Ведение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19.Клинические рекомендации Российского научного медицинского общества терапевтов и Научного общества гастроэнтерологов России (2-е издание)

В представленных клинических рекомендациях Российского научного медицинского общества терапевтов (РНМОТ) и Научного общества гастроэнтерологов России (НОГР) рассмотрены основные профилактические и лечебно- диагностические подходы к ведению пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Рекомендации утверждены на XV Национальным конгрессом терапевтов, XXIII съезде НОГР на основании 1-го издания, принятого на 22-м Международном Славяно-Балтийским научном форуме «Санкт-Петербург - Гастро-2020 ON-LINE».

1. Grinevich V.B., Kravchuk Yu.A., Ped V.I., et al. Management of patients with digestive diseases during the COVID-19 pandemic: Clinical Practice Guidelines by the Gastroenterological Scientific Society of Russia. Experimental and Clinical Gastroenterology. 2020;(7):4-51. (In Russ.) Doi:10.31146/1682-8658-ecg-179-7-4-51@@ Гриневич В.Б., Кравчук Ю.А., Педь В.И., Сас Е.И., Саликова С.П., Губонина И.В., Ткаченко Е.И., Ситкин С.И., Лазебник Л.Б., Голованова Е.В. Ведение пациентов с заболеваниями органов пищеварения в период пандемии COVID-19. Клинические рекомендации Научного общества гастроэнтерологов России. Экспериментальная и клиническая гастроэнтерология. 2020;(7):4-51. https://doi.org/10.31146/1682-8658-ecg-179-7-4-51

2. Grinevich V.B., Gubonina I.V., Doshchitsin V.L., Kotovskaya Yu.V., Kravchuk Yu.A., Ped V.I., Sas E.I., Syrov A.V., Tarasov A.V., Tarzimanova A.I., Tkacheva O.N., Trukhan D.I. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. (In Russ.) Doi:10.15829/1728-8800-2020-2630@@ Гриневич В. Б., Губонина И. В., Дощицин В. Л., Котовская Ю. В., Кравчук Ю. А., Педь В. И., Сас Е. И., Сыров А. В., Тарасов А. В., Тарзиманова А. И., Ткачёва О. Н., Трухан Д. И. Особенности ведения коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19). Национальный Консенсус 2020. Кардиоваскулярная терапия и профилактика. 2020;19(4):2630. doi:10.15829/1728-8800-2020-2630

3. Khlynova O.V., Karpunina N.S., Vasilets L.M. COVID-19 and organs damage: what do we know, coming to the fl attening of the curve? Experimental and Clinical Gastroenterology. 2020;(8):4-9. (In Russ.) Doi:10.31146/1682-8658-ecg-180-8-4-9 @@ Хлынова О. В., Карпунина Н. С., Василец Л. М. COVID-19 и поражение внутренних органов: что мы знаем, выходя на плато? Экспериментальная и клиническая гастроэнтерология. 2020;180(8): 4-9. DOI: 10.31146/1682-8658-ecg-180-8-4-9

4. Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis [published correction appears in Lancet Gastroenterol Hepatol. 2020 Jul;5(7):e6]. Lancet Gastroenterol Hepatol. 2020;5(7):667-678. Doi:10.1016/S2468-1253(20)30126-6

5. Suresh Kumar VC, Mukherjee S, Harne PS, et al. Novelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19. BMJ Open Gastroenterol. 2020;7(1):e000417. doi:10.1136/ bmjgast-2020-000417

6. Cheung K.S., Hung I. F., Chan P. P. Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples from the Hong Kong Cohort and Systematic Review and Meta-analysis. Gastroenterology. 2020 Apr 3: S0016-5085(20)30448-0. doi: 10.1053/j.gastro.2020.03.065

7. Sultan S., Altayar O., Siddique S. M. AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19. Gastroenterology. 2020. May 11: S0016-5085(20)30593-X. doi: 10.1053/j.gastro.2020.05.001

8. Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(6):e2011335. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.11335

9. Kumar A, Arora A, Sharma P, Anikhindi SA, Bansal N, Singla V, Khare S, Srivastava A. Gastrointestinal and hepatic manifestations of Corona Virus Disease-19 and their relationship to severe clinical course: A systematic review and meta-analysis. Indian J Gastroenterol. 2020 Jun;39(3):268-284. doi: 10.1007/s12664-020-01058-3. Epub 2020 Aug 4. PMID: 32749643; PMCID: PMC7399358

10. Dong ZY, Xiang BJ, Jiang M, Sun MJ, Dai C. The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021 Jan;55(1):67-76. doi: 10.1097/MCG.0000000000001424. PMID: 33116063; PMCID: PMC7713642

11. Elshazli RM, Kline A, Elgaml A, Aboutaleb MH, Salim MM, Omar M, Munshi R, Mankowski N, Hussein MH, Attia AS, Toraih EA, Settin A, Killackey M, Fawzy MS, Kandil E. Gastroenterology manifestations and COVID-19 outcomes: A meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021 Feb 2. doi: 10.1002/jmv.26836. Epub ahead of print. PMID: 33527440

12. Press release RGA and ROPIP. New disease, new symptoms, new therapeutic options. 2021. Available at: https: //www.rsls.ru/files/Prz2.pdf @@ Пресс-релиз РГА и РОПИП. Новое заболевание, новые симптомы, новые терапевтические возможности. 2021. https://www.rsls.ru/files/Prz2.pdf

13. Grinevich V.B., Kravchuk Yu.A., Ratnikova A.K. COVID-19: Clinical manifestations of lesions of the digestive system and directions for their correction. Materials of the 15th National Congress of Therapists. Collection of abstracts. Supplement to the journal "Therapy". 2020, No. 8, pp. 19-20. (In Russ.)@@ Гриневич В.Б., Кравчук Ю.А., Ратникова А.К. COVID-19: Клинические проявления поражения органов пищеварения и направления их коррекции // Материалы 15 Национального Конгресса Терапевтов. Сборник тезисов. Приложение к журналу «Терапия». - 2020. - №8. - С. 19-20

14. Wang H, Qiu P, Liu J, Wang F, Zhao Q. The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2020 Oct;44(5):653-661. doi: 10.1016/j.clinre.2020.04.012. Epub 2020 May 12. PMID: 32418852; PMCID: PMC7214284

15. Wong YJ, Tan M, Zheng Q, Li JW, Kumar R, Fock KM, Teo EK, Ang TL. A systematic review and meta-analysis of the COVID-19 associated liver injury. Ann Hepatol. 2020 Nov-Dec;19(6):627-634. doi: 10.1016/j.aohep.2020.08.064. Epub 2020 Aug 31. PMID: 32882393; PMCID: PMC7458067

16. Wu Y, Li H, Guo X, Yoshida EM., et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020 Sep;14(5):621-637. doi: 10.1007/s12072-020-10074-6. Epub 2020 Jul 24. PMID: 32710250; PMCID: PMC7380163

17. Kulkarni AV, Kumar P, Tevethia HV, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020 Aug;52(4):584-599. doi: 10.1111/apt.15916. Epub 2020 Jul 8. PMID: 32638436; PMCID: PMC7361465.

18. Dai C. The Prevalence of Gastrointestinal Symptoms, Abnormal Liver Function, Digestive System Disease and Liver Disease in COVID-19 Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021 Jan;55(1):67-76. doi: 10.1097/MCG.0000000000001424. PMID: 33116063; PMCID: PMC7713642

19. Liu J, Cui M, Yang T, Yao P. Correlation between gastrointestinal symptoms and disease severity in patients with COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol. 2020 Jul;7(1):e000437. doi: 10.1136/bmjgast-2020-000437. PMID: 32665397; PMCID: PMC7359194.

20. Tariq R, Saha S, Furqan F, Hassett L, Pardi D, Khanna S. Prevalence and Mortality of COVID-19 Patients With Gastrointestinal Symptoms: A Systematic Review and Meta-analysis. Mayo Clin Proc. 2020 Aug;95(8):1632-1648. doi: 10.1016/j.mayocp.2020.06.003. Epub 2020 Jun 10. PMID: 32753138; PMCID: PMC7284248.

21. Simanenkov V.I., Maev I.V., Tkacheva O.N., et al. Syndrome of increased epithelial permeability in clinical practice. Multidisciplinary national Consensus. Cardiovascular Therapy and Prevention. 2021;20(1):2758. (In Russ.) doi: 10.15829/1728-8800-2021-2758@@ Симаненков В.И., Маев И.В., Ткачева О.Н., Алексеенко С.А., Андреев Д.Н., Бордин Д.С., Власов Т.Д., Воробьёва Н.М., Гриневич В.Б., Губонина И.В., Дробижев М.Ю., Ефремов Н.С., Каратеев А.Е., Котовская Ю.В., Кравчук Ю.А., Кривобородов Г.Г., Кульчавеня Е.В., Лила А.М., Маевская М.В., Полуэктова Е.А., Попкова Т.В., Саблин О.А., Соловьева О.И., Суворов А.Н., Тарасова Г.Н., Трухан Д.И., Федотова А.В. Синдром повышенной эпителиальной проницаемости в клинической практике. Мультидисциплинарный национальный консенсус. Кардиоваскулярная терапия и профилактика. 2021;20(1):2758. Doi: 10.15829/1728-8800-2021-2758

22. Squier CA, Kremer MJ. Biology of oral mucosa and esophagus. J Natl Cancer Inst Monogr. 2001;(29):7-15. doi:10.1093/oxfordjournals.jncimonographs.a003443

23. Zakharov A. A., Ilna N. A. Analysis of the oral microfl ora of the examined people with various diseases. Advances in current natural sciences. 2007, No. 12 (part 3), pp. 141- 143. (In Russ.)@@ Захаров А.А., Ильна Н. А. Анализ микрофлоры ротовой полости обследованных людей с различными заболеваниями // Успехи современного естествознания. - 2007, № 12 (приложение, часть 3). - С. 141-143.

24. AADR PRESS RELEASES. Journal of Dental Research Systematic Analysis Examines Global Burden of Oral Conditions. Available at: https://www.iadr.org/AADR/ About-Us/News/ArtMID/134369/ArticleID/338/Journal-of-Dental-Research-Systematic-AnalysisExamines-Global-Burden-of-Oral-Conditions. (Monday, March 20, 2017)

25. Risk Factors. Available at: https://www.fdiworlddental. org/oral-health/risk-factors. [Accessed 10 August 2020].

26. Xu H., Zhong L., Deng J., et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci 12, 8 (2020). Doi: 10.1038/s41368-020-0074-x

27. Sabino-Silva R, Jardim ACG, Siqueira WL. Coronavirus COVID-19 impacts to dentistry and potential salivary diagnosis. Clin Oral Investig. 2020;24(4):1619-1621. doi:10.1007/s00784-020-03248-x

28. Gherlone EF, Polizzi E, Tetè G, De Lorenzo R, Magnaghi C, Rovere Querini P, Ciceri F. Frequent and Persistent Salivary Gland Ectasia and Oral Disease After COVID-19. J Dent Res. 2021 Mar 3:22034521997112. doi: 10.1177/0022034521997112. Epub ahead of print. PMID: 33655804; PMCID: PMC7930603

29. Xiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. Emerg Infect Dis. 2020;26(8):1920-1922. doi:10.3201/eid2608.200681

30. Arimura H. Eff ect of lysozyme from human placenta on ectromelia virus. Acta Virol. 1973;17(2):130-137.

31. Urita Y, Watanabe T, Maeda T, et al. Rebamipide and mosapride enhance pilocarpine-induced salivation. N Am J Med Sci. 2009;1(3):121-124.

32. Lazebnik L. B., Tkachenko E. I., Abdulganiyeva D. I., et al, Yakovenko E. P. VI National guidelines for the diagnosis and treatment of acid-related and Helicobacter Pylori-associated diseases (VI Moscow agreement). Experimental and Clinical Gastroenterology. 2017;(2):321. (In Russ.)@@ Лазебник Л. Б., Ткаченко Е. И., Абдулганиева Д. И. и др. VI Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с HelicobacterPylori заболеваний VI Московские соглашения. Экспериментальная и клиническая гастроэнтерология. - 2017. - № 138 (2). - С. 3-21.

33. Ivashkin V.T., Maev I.V., Trukhmanov A.S., et al. Recommendations of the Russian Gastroenterological Association in Diagnosis and Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70-97. (In Russ.) doi: 10.22416/1382-4376-2020-30-4-70-97@@ Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020;30(4):70-97. doi: 10.22416/1382-4376-2020-30-4-70-97

34. Grinevich V. B., Kravchuk Yu. A., et al. Features of management of patients with gastroenterological pathology in the conditions of the COVID-19 pandemic. Experimental and Clinical Gastroenterology. 2020;174(4):318. (In Russ.) doi:10.31146/1682-8658ecg-176-4-3-18@@ Гриневич В.Б., Кравчук Ю. А., Ткаченко Е. И. и др. Особенности ведения больных с гастроэнтерологической патологией в условиях пандемии COVID-19. Экспериментальная и клиническая гастроэнтерология. - 2020. - № 176 (4). DOI:10.31146/1682-8658ecg-176-4

35. Christopher H. Blevins et al. Th e Esophageal Epithelial Barrier in Health and Disease. Clinical Gastroenterology and Hepatology. 2018;16:608-617. Doi:10.1016/j.cgh.2017.06.035

36. Jiang G, Cai Y, Yi X, et al. The impact of laryngopharyngeal reflux disease on 95 hospitalized patients with COVID-19 in Wuhan, China: A retrospective study [published online ahead of print, 2020 May 12]. J Med Virol. JMed Virol. 2020;92:2124-2129. Doi:10.1002/jmv.25 998

37. Lechien JR, Bartaire E, Bobin F, Hans S, Saussez S. Th e association between laryngopharyngeal refl ux and COVID-19 is still not demonstrated [published online ahead of print, 2020 May 28]. J Med Virol, 92: 2392-2393. https://doi.org/10.1002/jmv.26080

38. Interim Guidelines: Prevention, Diagnosis and Treatment of Novel COVID-19 Coronavirus Infection. Version 10 (02/08/2021). Moscow, 2021. 261 p. (In Russ.)@@ Временные методические рекомендации: Профилактика, диагностика и лечение новой коронавирусной инфекции COVID-19. Версия 10 (08.02.2021). М., 2021.- 261 с.

39. Wen X, Chen X, Zhou X. [Rebamipide inhibited expression of TLR4 and TNF-alpha release in pulmonary epithelial cell line A549 induced by lipopolysaccharide]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2009 May;34(5):457-160. (in Chinese.) PMID: 19483297.

40. Yasuda T, Chiba H, Satomi T, et al. Preventive effect of rebamipide gargle on chemoradiotherpy-induced oral mucositis in patients with oral cancer: a pilot study. J Oral Maxillofac Res. 2012;2(4):e3. Published 2012 Jan 1. doi:10.5037/jomr.2011.2403

41. Akagi S, Fujiwara T, Nishida M, et al. The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis. J Pharm Health Care Sci. 2019;5:16. Published 2019 Jul 25. doi:10.1186/s40780-019-0146-2

42. Ivashkin V.T., Trukhmanov A.S., Gonik M.I. Ter Arkh. 2020;92(4):98-104. Published 2020 May 19. (In Russ.) doi:10.264 42/00403660.2020.04.000568@@ Ивашкин В.Т., Трухманов А.С., Гоник М.И. Применение ребамипида в лечении гастроэзофагеальной рефлюксной болезни. Терапевтический архив 4, 2020 DOI:10.26442/00403660.2020.04.00 0568

43. Soon Man Yoon et al. The Effect of Rebamipide in Patients with Gastroesophageal Reflux Disease, Including NonErosive Reflux Disease: A Multi-Center, Randomized, Single-Blind, Placebo-Controlled Study AGA Abstracts. May 2019, Volume 156, Issue 6, Supplement 1, Page S-5

44. SuJin.Hong et al. Th e Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016 Nov; 10(6): 910-916

45. Gweon T. G. et al. Additive Effects of Rebamipide Plus Proton Pump Inhibitors on the Expression of Tight Junction Proteins in a Rat Model of Gastro-Esophageal Reflux Disease. Gut Liver. 2018 Jan 15;12(1):46-50.

46. Ji-Won Kim et al. Influence of proton pump inhibitor or rebamipide use on gut microbiota of rheumatoid arthritis patients. J Immunol. May 1, 2020, 204 (1 Supplement) 224.18

47. Song TJ, Kim J. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study. PLoS One. 2019;14(5):e0216750. Published 2019 May 8. doi:10.1371/journal.pone.0216750

48. Zhou J., Li C., Zhao G. et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017, Vol. 3(11): eaao4966. Published 2017 Nov 15. doi:10.1126/ sciadv.aao4966.

49. Almario C.V., Chey W.D., Spiegel B. M. R. Increased risk of COVID-19 among users of proton pump inhibitors. Am J Gastroenterol. 2020 (pre-print posted online July 7, 2020)

50. Lee SW, Ha EK, Yeniova AÖ, Moon SY, Kim SY, Koh HY, Yang JM, Jeong SJ, Moon SJ, Cho JY, Yoo IK, Yon DK. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2020 Jul 30:gutjnl-2020-322248. doi: 10.1136/gutjnl-2020-322248. Epub ahead of print. PMID: 32732368

51. Kow CS, Hasan SS. Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. J Intern Med. 2020 Oct 20. doi: 10.1111/joim.13183. Epub ahead of print. PMID: 33078881.

52. Janowitz T, Gablenz E, Pattinson D, Wang TC, Conigliaro J, Tracey K, Tuveson D. Famotidine use and quantitative symptom tracking for COVID-19 in non-hospitalised patients: a case series. Gut. 2020 Sep;69(9):1592-1597. doi: 10.1136/gutjnl-2020-321852. Epub 2020 Jun 4. PMID: 32499303; PMCID: PMC7299656.

53. Moroz E.V., Karateev A.E. Proton pump inhibitors and the risk of pneumonia: how dangerous is it to use these drugs during the COVID-19 pandemic? Therapy. 2021; 1: 78-82. (In Russ.) Doi: 10.18565/therapy.2021.1.78-82@@ Мороз Е.В., Каратеев А.Е.. Ингибиторы протонной помпы и риск развития пневмонии: насколько опасно использовать эти препараты в период пандемии. Терапия. 2021; 1: 78-82. Doi: 10.18565/therapy.2021.1.78-82

54. Patel P, Sengupta N. PPIs and Beyond: A Framework for Managing Anticoagulation-Related Gastrointestinal Bleeding in the Era of COVID-19. Dig Dis Sci. 2020 Aug;65(8):2181-2186. doi: 10.1007/s10620-020-06408-x. PMID: 32537704; PMCID: PMC7293960.

55. Gadiparthi C., Perisetti A., Sayana H. et al. Gastrointestinal bleeding in patients with severe SARS-CoV-2. Am J Gastroenterol. 2020; 115(8): 1283-85. doi: 10.14309/ajg.0000000000000719.

56. GrinevichVB, SasVE, Kon, et al. Prebiotic correction of the intestinal microbial-tissue complex as a basic component of modern pathogenetic therapy of metabolic syndrome and associated cardiovascular and cerebrovascular diseases. Study guide. SPb., 2012, 20 P. (In Russ.)@@ Гриневич В. Б. Пребиотическая коррекция микробно-тканевого комплекса кишечника, как базовая составляющая современной патогенетической терапии метаболического синдрома и ассоциированных кардиоваскулярных и цереброваскулярных заболеваний. Учебно-методическое пособие / В. Б. Гриневич, Е. И. Сас, В. Е. Кон [и др.]. - СПб., 2012. - 20 с.

57. Hong SJ, Park SH, Moon JS, et al. The Benefits of Combination Therapy with Esomeprazole and Rebamipide in Symptom Improvement in Reflux Esophagitis: An International Multicenter Study. Gut Liver. 2016;10(6):910-916. doi:10.5009/gnl15537

58. Yoshida N, Kamada K, Tomatsuri N, et al. Management of recurrence of symptoms of gastroesophageal refl ux disease: synergistic eff ect of rebamipide with 15 mg lansoprazole. Dig Dis Sci. 2010;55(12):3393-3398. doi:10.1007/s10620-010-1166-9

59. Fass R, Shapiro M, Dekel R, Sewell J. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease--where next?. Aliment Pharmacol Ther. 2005;22(2):79-94. doi:10.1111/j.1365-2036.2005.02531.x

60. Friedlander EA, Pallentino J, Miller SK, VanBeuge SS. The evolution of proton pump inhibitors for the treatment of gastroesophageal reflux disease. J Am Acad Nurse Pract. 2010 Dec;22(12):674-83. doi: 10.1111/j.1745-7599.2010.00578.x. Epub 2010 Nov 24. PMID: 21129076.

61. Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr Med Res Opin. 2009 Mar;25(3):627-38. doi: 10.1185/03007990802693883. PMID: 19232037.

62. Wittbrodt ET, Baum C, Peura DA. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin Exp Gastroenterol. 2009;2:117-28. doi: 10.2147/ceg.s5765. Epub 2009 Nov 17. PMID: 21694835; PMCID: PMC3108635.

63. Croxtall JD, Scott LJ. Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease. Drugs. 2010 Aug 20;70(12):1593-601. doi: 10.2165/11295960-000000000-00000. PMID: 20687622. FDA full prescribing information for Dixilant, Prolosec, Nexium, Aciphex.

64. Rochoy M, Dubois S, Glantenet R, Gautier S, Lambert M. Le rebond d’acidité gastrique après arrêt d’un inhibiteur de la pompe à protons : revue narrative de littérature [Gastric acid rebound after a proton pump inhibitor: Narrative review of literature]. Therapie. 2018 May-Jun;73(3):237-246. (in French.) doi: 10.1016/j.therap.2017.08.005. Epub 2017 Oct 26. PMID: 29195714.

65. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernandez C, Walsh K, Welch V, Moayyedi P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. Can Fam Physician. 2017 May;63(5):354-364. PMID: 28500192; PMCID: PMC5429051.

66. Metz DC, Pilmer BL, Han C, Perez MC. Withdrawing PPI therapy after healing esophagitis does not worsen symptoms or cause persistent hypergastrinemia: analysis of dexlansoprazole MR clinical trial data. Am J Gastroenterol. 2011 Nov;106(11):1953-60. doi: 10.1038/ajg.2011.220. Epub 2011 Aug 16. PMID: 21844923; PMCID: PMC3209587.

67. Matysiak-Budnik T, Heyman M, Mégraud F. Review article: rebamipide and the digestive epithelial barrier. Aliment Pharmacol Ther. 2003;18 Suppl 1:55-62. doi:10.1046/j.1365-2036.18.s1.6.x

68. Shim S, Jang HS, Myung HW, et al. Rebamipide ameliorates radiation-induced intestinal injury in a mouse model. Toxicol Appl Pharmacol. 2017;329:40-47. doi:10.1016/j. taap.2017.05.012

69. Jaafar MH, Safi SZ, Tan MP, Rampal S, Mahadeva S. Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2018;63(5):1250-1260. doi:10.1007/s10620017-4871-9

70. Takeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocul Pharmacol Ther. 2012;28(3):259-263. doi:10.1089/jop.2011.0142

71. Matsuda T, Ohno S, Hirohata S, et al. Effi cacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled study. Drugs R D. 2003;4(1):19-28. doi:10.2165/00126839200304010-00002

72. Badarinarayanan G., Gowrisankar R., Muthulakshmi K. Esophageal Candidiasis in non-immune suppressed patients in a semi-urban town, southern India. Mycopathologia. 2000;149(1):1-4. doi: 10.1023/A:1007245919761.

73. Thuraisingam A. I., Denning D. W. Candida glabrata oesophagitis in a patient without HIV infection. European Journal of Clinical Microbiology and Infectious Diseases. 2000;19(7):561-569

74. Macêdo D. P. C., Da Silva V. K. A., Farias A. M. D. A., De Melo L. R. B., Wilheim A. B., Neves R. P. Candida glabrata esophagitis: new case reports and management. Brazilian Journal of Microbiology. 2008;39(2):279-281. doi: 10.1590/S1517-83822008000200015

75. Pace F., Pallotta S., Antinori S. Nongastroesophageal reflux disease-related infectious, inflammatory and injurious disorders of the esophagus. Current Opinion in Gastroenterology. 2007;23(4):446-451. doi: 10.1097/MOG.0b013e32818a6d8b.

76. Fidel P. L., Jr., Vazquez J. A., Sobel J. D. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clinical Microbiology Reviews. 1999;12(1):80-96.

77. Pappas P. G., Kauffman C. A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(5):503-535. doi: 10.1086/596757

78. Pfaller M. A., Diekema D. J. Epidemiology of invasive candidiasis: a persistent public health problem. Clinical Microbiology Reviews. 2007;20(1):133-163. doi: 10.1128/CMR.00029-06

79. Wilson A., Delport J., Ponich T. Candida glabrata Esophagitis: Are We Seeing the Emergence of a New Azole-Resistant Pathogen? Int J Microbiol. 2014; 2014: 371631. doi: 10.1155/2014/371631

80. Wilcox C. M., Straub R. F., Clark W. S. Prospective evaluation of oropharyngeal findings in human immunodeficiency virus-infected patients with esophageal ulceration. American Journal of Gastroenterology. 1995;90(11):1938-1941.

81. Prasad R, Rawal MK. Efflux pump proteins in antifungal resistance. Front. pharmacol. 2014;5:202. doi: 10.3389/fphar.2014.00202

82. Prasad R, Goffeau A. Yeast ATP-binding cassette transporters conferring multidrug resistance. Annu. Rev. Microbiol. 2012;66:39-63. doi: 10.1146/annurev-micro-092611-150111

83. Kim KY, et al. Acid suppression therapy as a risk factor for Candida esophagitis. Dig. Dis. Sci. 2013;58:1282-1286. doi: 10.1007/s10620-012-2520-x.

84. Pereira O, Figueira-Coelho J, Picado B, Costa JN. Black oesophagus. BMJ Case Rep. 2013;2013:bcr2012008188. doi: 10.1136/bcr-2012-008188

85. Chen KH, Weng MT, Chou YH, Lu YF, Hsieh CH. Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report. Medicine. 2016;95:e3133. doi: 10.1097/MD.0000000000003133

86. Shah AR, Landsman M, Waghray N. A Dire Presentation of Diabetic Ketoacidosis with “Black Esophagus. Cureus. 2019;11:e4761. doi: 10.7759/cureus.4761.

87. Biswas SK, Yokoyama K, Kamei K, Nishimura K, Miyaji M. Inhibition of hyphal growth of Candida albicans by activated lansoprazole, a novel benzimidazole proton pump inhibitor. Med. Mycol. 2001;39:283-285. doi: 10.1080/mmy.39.3.283.285.

88. Liu NN, Kohler JR. Antagonism of Fluconazole and a Proton Pump Inhibitor against Candida albicans. Antimicrob. Agents Chemother. 2016;60:1145-1147. doi: 10.1128/AAC.02043-15.

89. Monk BC, et al. Surface-active fungicidal D-peptide inhibitors of the plasma membrane proton pump that block azole resistance. Antimicrob. Agents Chemother. 2005;49:57-70. doi: 10.1128/AAC.49.1.57-70.2005

90. Mathe L, Van Dijck P. Recent insights into Candida albicans biofilm resistance mechanisms. Curr. Genet. 2013;59:251-264. doi: 10.1007/s00294-013-0400-3

91. Cordeiro Rde A, et al. Exogenous tyrosol inhibits planktonic cells and biofilms of Candida species and enhances their susceptibility to antifungals. FEMS Yeast Res. 2015;15:fov012. doi: 10.1093/femsyr/fov012

92. Matsubara VH, Wang Y, Bandara HM, Mayer MP, Samaranayake LP. Probiotic lactobacilli inhibit early stages of Candida albicans biofilm development by reducing their growth, cell adhesion, and filamentation. Appl. Microbiol. Biotechnol. 2016;100:6415-6426. doi: 10.1007/s00253-016-7527-3

93. Hayama K, et al. A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model. FEMS Microbiol. Lett. 2012;328:130-137. doi: 10.1111/j.1574-6968.2011.02490.x

94. Yandrapu H., Sarosiek J. Protective Factors of the Gastric and Duodenal Mucosa: An Overview. Curr Gastroenterol Rep. 2015;17(6):24. doi:10.1007/s11894- 015-0452-2

95. IvashkinV. T., MayevI. V., KaprinA. D., et al. Early Detection of Oncological Diseases of the Digestive System (Guidelines of the Russian Gastroenterological Association and the Russian Association of Oncologists for Primary Care Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):53-74. (In Russ.) doi:10.22416/13824376-2019-29-5-53-74@@ Ивашкин В. Т., Маев И. В., Каприн А. Д. и др. Раннее выявление онкологических заболеваний органов пищеварения (методическое руководство Российской гастроэнтерологической ассоциации и Ассоциации онкологов России для врачей первичного звена здравоохранения). Рос журн гастроэнтерол гепатол колопроктол. - 2019. - Т. 29, № 5. - С. 53-74.

96. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [published correction appears in Lancet Respir Med. 2020 Feb 25;:]. Lancet Respir Med. 2020;8(4):420- 422. doi:10.1016/S2213-2600(20)30076-X

97. Xia L., Wu K. Gastroenterology Practice in COVID-19 Epidemic. World Gastroenterology News. May 2020. pp. 7-10

98. Consensus of Diagnosis and Treatment of digestive disorders related to COVID-19. Natl Med J Chin. 2020. Vol. 40: E001. Published Online

99. Cha MH, Regueiro M, Sandhu DS. Gastrointestinal and hepatic manifestations of COVID-19: A comprehensive review. World J Gastroenterol. 2020;26(19):2323-2332. doi:10.3748/wjg.v26.i19.2323

100. Belova G.V. Recommendations for endoscopy and clinical practice in gastroenterology. Experimental and Clinical Gastroenterology. 2020;174(5):4-7. (In Russ.) doi:10.31146/1682-8658-ecg-177-5-4-7@@ Белова Г. В. Рекомендации по эндоскопии и клинической практике в гастроэнтерологии. Экспериментальная и клиническая гастроэнтерология. 2020;177(5): 4-7. DOI: 10.31146/1682-8658-ecg-177-5-4-7

101. MartynovA. I., SheptulinA. A., MayevI. V., et al. New Prospects of Cytoprotection in the Treatment and Prevention of Gastric and Intestinal Diseases (Resolution of an Expert Council and Literature Review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(2):7-14. (In Russ.) doi:10.22416/1382-4376-2020-30-2-7-14@@ Мартынов А. И., Шептулин А. А., Маев И. В. и др. Новые возможности цитопротекции в лечении и профилактике заболеваний желудка и кишечника (резолюция Экспертного совета и обзор литературы). Рос журн гастроэнтерол гепатол колопроктол. - 2020. Т. 30, № 2. - С. 7-14.

102. World Gastroenterology Organisation Global Guidelines ‘Probiotics and Prebiotics’. 2017 Feb. A vailable at: http://www.worldgastroenterology.org/guidelines/ global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english [Accessed 10 August 2020].

103. IvashkinV. T., MayevI. V., LapinaT. L., et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70. (In Russ.) doi:10.22416/1382-4376-2018-28-1-55-70@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacterpylori у взрослых. Рос журн гастроэнтерол гепатол колопроктол. - 2018. - Т. 28, № 1. - С. 55-70.

104. Simadibrata M. et al. Anti free radical &anti infl ammatory eff ect of rebamipide in chronic gastritis. Open Journal of Gastroenterology. 2013, - Vol. 3, pp. 72-77.

105. Otani K, Tanigawa T, Watanabe T, et al. Microbiota Plays a Key Role in Non-Steroidal Anti-Infl ammatory Drug-Induced Small Intestinal Damage. Digestion. 2017;95(1):22-28. doi:10.1159/000452356

106. Hayashi S, Sugiyama T, Amano K, et al. Eff ect of rebamipide, a novel antiulcer agent, on Helicobacter pylori adhesion to gastric epithelial cells. Antimicrob Agents Chemother. 1998;42(8):1895-1899. doi:10.1128/ AAC.42.8.1895

107. Simanenkov V. I., Bakulina N. V., Fil Т. S., Khubieva A. Kh. Evaluation of efficiency of H. pylori eradication in case of addition of cytoprotective preparation rebamipide to the treatment: results of the bastion trial. Farmateka. 2017:S5;65-70. (In Russ.)@@ Симаненков В. И., Бакулина Н. В., Филь Т. С., Хубиева А. Х. Оценка эффективности эрадикации Н. Pylori при добавлении к схеме лечения цитопротективного препарата ребамипид: результаты исследования Бастион. Фарматека. - 2017. - S5. - C. 65-70.

108. Andreev DN, Maev IV, Dicheva DT. Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies. J Clin Med. 2019;8(9):1498. Published 2019 Sep 19. doi:10.3390/ jcm8091498

109. IvashkinV. T., MayevI. V., LapinaT. L., et al. Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 2017). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):4-21. (In Russ.) doi:10.22416/1382-4376-2017-27-4-4-21@@ Ивашкин В. Т., Маев И. В., Лапина Т. Л. и др. Лечение инфекции Helicobacterpylori: мейнстрим и новации (Обзор литературы и резолюция Экспертного совета Российской гастроэнтерологической ассоциации 19 мая 2017 г.). Рос журн гастроэнтерол гепатол колопроктол. - 2017. - Т. 27, № 4. - С. 4-21.

110. Karateev A. E., Nasonov E. L., Ivashkin V. T., et al. Rational use of nonsteroidal anti-infl ammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56:1-29. (In Russ.) doi:10.14412/19954484-2018-1-29 @@ Каратеев А. Е., Насонов Е. Л., Ивашкин В. Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. - 2018. - № 56. - С. 1-29.

111. Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Recommendations for the prevention and treatment of esophago-gastro-entero-colopathy induced by nonsteroidal antiinfl ammatory drugs “NSAID”. Experimental and Clinical Gastroenterology. 2018;(3):4-18. (In Russ.)@@ Лазебник Л. Б., Голованова Е. В., Алексеенко С. А. и др. Рекомендации по профилактике и лечению эзофаго- гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами. Экспериментальная и клиническая гастроэнтерология. - 2018. - № 151(03). - С. 04-18.

112. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and Liver. J Hepatol. 2020 Jun 15:S0168-8278(20)30377-9. doi: 10.1016/j.jhep.2020.06.006

113. Gu J, Han B, Wang J. COVID-19: Gastrointestinal Manifestations and Potential Fecal-Oral Transmission. Gastroenterology. 2020;158(6):1518-1519. doi:10.1053/ j.gastro.2020.02.054

114. Cai Q., Huang D., Yu H. et al. COVID-19: Abnormal liver function tests. J Hepatol. 2020; S0168-8278(20)30218-X. doi:10.1016/j.jhep.2020.04.006

115. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, Poucke SV, Liu WY, Zheng MH. COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020 Mar 28;8(1):18-24. doi: 10.14218/JCTH.2020.00018

116. Portincasa P, Krawczyk M, Machill A, Lammert F, Di Ciaula A. Hepatic consequences of COVID-19 infection. Lapping or biting? Eur J Intern Med. 2020 Jul;77:18-24. doi: 10.1016/j.ejim.2020.05.03

117. Amin M. COVID-19 and the liver: overview. Eur J Gastroenterol Hepatol. 2020 Jun 16. doi: 10.1097/MEG.0000000000001808

118. Boggs W. Liver Injury Common With COVID-19. March 13, 2020 https://www.medscape.com/viewarticle/926628

119. Sun J., Aghemo A., Forner A., Valenti L. COVID-19 and liver disease. Liver Int. 2020 Jun;40(6):1278-1281. doi: 10.1111/liv.14470. PMID: 32251539.

120. Parohan M, Yaghoubi S, Seraji A. Liver injury is associated with severe coronavirus disease 2019 (COVID-19) infection: A systematic review and meta-analysis of retrospective studies. Hepatol Res. 2020 Aug;50(8):924-935. doi: 10.1111/hepr.13510. Epub 2020 Jun 25. PMID: 32386449; PMCID: PMC7273097.

121. Patel KP, Patel PA, Vunnam RR, Hewlett AT, Jain R, Jing R, Vunnam SR. Gastrointestinal, hepatobiliary, and pancreatic manifestations of COVID-19. J Clin Virol. 2020 Jul;128:104386. doi: 10.1016/j.jcv.2020.104386. Epub 2020 Apr 29. PMID: 32388469; PMCID: PMC7189193.

122. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281- 292.e6. doi:10.1016/j.cell.2020.02.058

123. Chai X., Hu L., Zhang Y. et al. Specifi c ACE2 Expression in Cholangiocytes May Cause Liver Damage Aft er 2019nCoV Infection. bioRxiv. 02.03.931766.

124. Paizis G, Tikellis C, Cooper ME, et al. Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2. Gut. 2005;54(12):1790-1796. doi:10.1136/gut.2004.062398

125. Boettler T, Newsome PN, Mondelli MU, et al. Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper. JHEP Rep. 2020;2(3):100113. doi:10.1016/j.jhepr.2020.100113

126. Fan Z., Chen L., Li J., Tian C., Zhang Y., Huang S. et al. Clinical Features of COVID-19-Related Liver Damage. 2020. Available at SSRN3546077. DOI: 10.2139/ ssrn.3546077.

127. Chen N., Zhou M., Dong X., Ou J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076.

128. Ong J, Young BE, Ong S. COVID-19 in gastroenterology: a clinical perspective. Gut. 2020;69(6):1144-1145. doi:10.1136/gutjnl-2020-321051

129. Wu J, Song S, Cao HC, Li LJ. Liver diseases in COVID-19: Etiology, treatment and prognosisю World J Gastroenterol. 2020 May 21;26(19):2286-2293. doi: 10.3748/wjg.v26.i19.2286

130. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3

131. Guan W. J., Ni Z.Y, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28. PMID: 32109013; PMCID: PMC7092819.

132. Albillos A., Lario M., Álvarez-Mon M. Cirrhosisassociated immune dysfunction: Distinctive features and clinical relevance. Journal of Hepatology. 2014;61:1385- 1396.

133. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-108. doi:10.1016/j.jpha.2020.03.001

134. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi:10.1016/ S0140-6736(20)30628-0

135. Marjot T, Buescher G, Sebode M, Barnes E, Barritt AS IV, Armstrong MJ, Baldelli L, Kennedy J, Mercer C, Ozga AK, Casar C, Schramm C, contributing Members and Collaborators of ERN RARE-LIVER / COVID-Hep / SECURE-Cirrhosis, SARS-CoV-2 infection in patients with autoimmune hepatitis. Journal of Hepatology. 2021 Jan 26:S0168-8278(21)00033-7. doi: 10.1016/j.jhep.2021.01.021. Epub ahead of print. PMID: 33508378; PMCID: PMC7835076.

136. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40(5):998-1004. doi:10.1111/liv.14435

137. Zhang C. , Shi L. , Wang F.S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol, 2020 May;5(5):428-430. doi: 10.1016/S2468-1253(20)30057-1. Epub 2020 Mar 4. PMID: 32145190; PMCID: PMC7129165.

138. Gao F. et al. Metabolic Associated Fatty Liver Disease Increases COVID-19 Disease Severity in Non-Diabetic Patients. J Gastroenterol Hepatol. 2021 Jan;36(1):204-207. doi: 10.1111/jgh.15112. Epub 2020 Jun 5. PMID: 32436622; PMCID: PMC7280625.

139. Moon AM, Webb GJ, Aloman C, et al. High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. J Hepatol. 2020;73(3):705- 708. doi:10.1016/j.jhep.2020.05.013

140. Hollander JE, Carr BG. Virtually Perfect? Telemedicine for Covid-19. N Engl J Med. 2020;382(18):1679-1681. doi:10.1056/NEJMp2003539

141. Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc. 2010;85(5):451-458. doi:10.4065/mcp.2009.0534

142. Mayevskaya M. V., Nadinskaia M. Yu., Lunkov V. D., et al. An Effect of Ursodeoxycholic Acid on Inflammation, Steatosis and Liver Fibrosis and Atherogenesis Factors in Patients with Non-Alcoholic Fatty Liver Disease: Results of the USPEH Study. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(6):22-29. (In Russ.) doi:10.22416/1382-4376-2019-29-6-22-29@@ Маевская М. В., Надинская М. Ю., Луньков В. Д. и др. Влияние урсодезоксихолевой кислоты на воспаление, стеатоз и фиброз печени и факторы атерогенеза у больных неалкогольной жировой болезнью печени: результаты исследования УСПЕХ. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2019. - Т. 29(6). - С. 22-29.

143. Mroz MS, Harvey BJ. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fi brosis bronchial epithelial cells. Steroids. 2019;151:108461. doi:10.1016/j.steroids.2019.108461

144. Schultz F, Hasan A, Alvarez-Laviada A, et al. Th e protective eff ect of ursodeoxycholic acid in an in vitro model of the human fetal heart occurs via targeting cardiac fi broblasts. Prog Biophys Mol Biol. 2016;120(1-3):149-163. doi:10.1016/j.pbiomolbio.2016.01.003

145. Işık S, Karaman M, Çilaker Micili S, et al. Beneficial effects of ursodeoxycholic acid via inhibition of airway remodelling, apoptosis of airway epithelial cells, and Th 2 immune response in murine model of chronic asthma. Allergol Immunopathol (Madr). 2017;45(4):339-349. doi:10.1016/j.aller.2016.12.003

146. Niu F, Xu X, Zhang R, Sun L, Gan N, Wang A. Ursodeoxyc holic acid stimulates alveolar fl uid clearance in LPS-induced pulmonary edema via ALX/cAMP/PI3K pathway. J Cell Physiol. 2019;234(11):20057-20065. doi:10.1002/jcp.28602

147. Subramanian S, Iles T, Ikramuddin S, Steer CJ. Merit of an Ursodeoxycholic Acid Clinical Trial in COVID-19 Patients. Vaccines (Basel). 2020;8(2):320. Published 2020 Jun 19. doi:10.3390/vaccines8020320

148. Abdulrab S, Al-Maweri S, Halboub E. Ursodeoxycholic acid as a candidate therapeutic to alleviate and/or prevent COVID-19-associated cytokine storm. Med Hypotheses. 2020 Oct;143:109897. doi: 10.1016/j.mehy.2020.109897. Epub 2020 May 30. PMID: 32505909; PMCID: PMC7261102.

149. Astrakhanova T.A., Shchelchkova N.A., Pchelin P.V., Vedunova M.V., Mukhina I.V. Cell bioenergetics in normoxia and hypoxia, Teaching aid. Nizhny Novgorod, 2016 @@ Астраханова Т.А., Щелчкова Н.А., Пчелин П.В., Ведунова М.В., Мухина И.В. Биоэнергетика клетки при нормоксии и гипоксии, Учебно-методическое пособие. Нижний Новгород, 2016.

150. Lazebnik L.B., Golovanova E.V., Tarasova L.V., et al. Adult Alcoholic Liver Disease. Experimental and Clinical Gastroenterology. 2020;174(2):4-28. (In Russ.) doi: 10.31146/1682-8658-ecg-174-2-4-28@@ Лазебник Л. Б., Голованова Е.В., Еремина Е.Ю. и др. Алкогольная болезнь печени (АБП) у взрослых. Экспериментальная и клиническая гастроэнтерология. 2020; 174(2): 4-28. DOI: 10.31146/1682-8658-ecg-174-2-4-28.

151. Lazebnik L.B., Golovanova E.V., Hlynova O.V., et al. Medicinal liver damage in adults. Experimental and Clinical Gastroenterology. 2020;174(2):29-54. (In Russ.) doi:10.31146/1682-8658-ecg-174-2-29-54 @@ Лазебник Л. Б., Голованова Е. В., Алексеенко С. А., и др. Лекарственные поражения печени (ЛПП) у взрослых. Экспериментальнаяи клиническая гастроэнтерология. 2020;174(2): 29-54. DOI: 10.31146/1682-8658-ecg-174-2-29-54

152. Ivashkin V.T., Baranovsky A.Yu., Raikhelson K.L., Palgova L.K., Maevskaya M.V., Kondrashina E.A., Marchenko N.V., Nekrasova T.P., Nikitin I.G. Drug-Induced Liver Injuries (Clinical Guidelines for Physicians). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(1):85-115. (In Russ.) doi: 10.22416/1382-4376-2019-29-1-101-131@@ Ивашкин В. Т., Барановский А. Ю., Райхельсон К. Л. и др. Лекарственные поражения печени (клинические рекомендации для врачей). Рос журн гастроэнтерол гепатол колопроктол 2019; 29(1): 101-131. DOI: 10.22416/1382-4376-2019-29-1-101-131

153. Ilchenko L.Yu., Okovityy S.V. Remaxol: mechanisms of action and application in clinical practice. Part 1. Archives of Internal Medicine. 2016; 6 (2): 16-21. (In Russ.)@@ Ильченко Л.Ю., Оковитый С.В. Ремаксол: механизмы действия и применение в клинической практике. Часть 1. Архивъ внутренней медицины. 2016; 6(2): 16-21.

154. Shapovalov K.G., Tsydenpinov G.A., Lukyanov S.A., Trusova Yu.S., Konnov V.A. Prospects for the use of succinates in treating severe course of new coronavirus infection. Experimental and Clinical Pharmacology, 2020;83 (10):40-43. (In Russ.) doi: 10.30906/0869-2092-2020-83-10-40-43@@ Шаповалов К.Г., Цыденпинов Г.А., Лукьянов С. А., Трусова Ю. С., Коннов В.А. Перспективы применения сукцинатов при тяжелом течении новой коронавирусной инфекции. Экспериментальная и клиническая фармакология, 2020.Том 83 (№10), с. 40-43. doi: 10.30906/0869-2092-2020-83-10-40-43

155. Smok A.M., Malkova A.M., Kudlay D.A., Starshinova A.A. Possibilities for correcting hepatotoxic reactions during therapy in patients with COVID-19 (case report). Translational Medicine. 2020;7(6):65-72. (In Russ.) doi:10.18705/2311-4495-2020-7-6-65-72@@ Смок А.М., Малкова А.М., Кудлай Д.А., Старшинова А.А. Возможности коррекции гепатотоксических реакций на фоне терапии у больных с COVID-19 (описание клинического случая). Трансляционная медицина. 2020;7(6):65-72. Doi: 10.18705/2311-4495-2020-7-6-65-72

156. Lazebnik L. B., Golovanova E. V., Alekseenko S. A., et al. Russian consensus “Hyperammonemia in adults”. THERAPY. 2020;(4):36-51. (In Russ.) DOI: 10.18565/therapy.2020.4.36-51@@ Лазебник Л.Б., Голованова Е.В., Алексеенко С.А. и др. Российский консенсус «Гипераммониемии у взрослых» Утвержден в качестве документа Российского научного медицинского общества терапевтов (РНМОТ) и Научного общества гастроэнтерологов России (НОГР) 20-21 ноября 2019 г. XIV Национальным конгрессом терапевтов и XXII съездом НОГР. Терапия, 2020, № 4, 26-51 DOI: https:// dx.doi.org/10.18565/therapy.2020.4.36-51

157. Saigal S, Kapoor D, Roy DS. Ademetionine in patients with liver disease: a review. Int J Res Med Sci. 2019;7:2482-93. doi: 10.18203/2320-6012.ijrms20192550.

158. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020; 18 (4): 844-847. DOI: 10.1111/jth.14768

159. Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020; 58 (7): 1021-1028. DOI: 10.1515/cclm-2020-0369

160. Maksimov V.A., Torshin I.Yu., Chuchalin A.G., Tkacheva O.N., Strazhesko I.D., Gromova O.A. The effectiveness and safety of a polypeptide drug (Laennec) for the treatment of COVID-19. Experimental and Clinical Gastroenterology. 2020;(6):55-63. (In Russ.) doi:10.31146/1682-8658-ecg-178-6-55-63@@ Максимов В. А., Торшин И. Ю., Чучалин А. Г., Лазебник Л. Б., Ткачева О. Н., Стражеско И. Д., Громова О. А. Эффективность и безопасность полипептидного препарата (Лаеннек) в терапии COVID-19. Экспериментальная и клиническая гастроэнтерология. 2020;178(6): 55- 63. DOI: 10.31146/1682-8658-ecg-178-6-55-63

161. Gromova O.A., Torshin I.Yu., Maksimov V.A., Chuchalin A.G., Zgoda V.G., Gromov А.N., Tikhonova O.V. Peptides contained in the composition of Laennec that contribute to the treatment of hyperferritinemia and iron overload disorders. FARMAKOEKONOMIKA. Modern Pharmacoeconomic and Pharmacoepidemiology. 2020;13(4):413-425. (In Russ.) doi:10.17749/2070-4909/farmakoekonomika.2020.070@@ Громова О.А., Торшин И.Ю., Максимов В.А., Чучалин А.Г., Згода В.Г., Тихонова О.В. Пептиды в составе препарата Лаеннек, способствующие устранению гиперферритинемии и перегрузки железом. ФАРМАКОЭКОНОМИКА. Современная Фармакоэкономика и Фармакоэпидемиология. 2020; 13 (4): 69-81. Doi:10.17749/2070-4909/farmakoekonomika.2020.070

162. Maksimov V.A., Torshin I.Yu., Chuchalin A.G., Lazebnik L.B., Tkacheva O.N., Strazhesko I.D., Gromova O.A. An experience of using Laennec in patients at high risk of a cytokine storm with COVID-19 and hyperferritinemia. PULMONOLOGIYA. 2020;30(5):587-598. (In Russ.) doi:10.18093/0869-0189-2020-30-5-587-598@@ Максимов В.А., Торшин И.Ю., Чучалин А.Г., Лазебник Л.Б., Ткачева О.Н., Стражеско И.Д., Громова О.А. Опыт применения препарата Лаеннек у пациентов с высоким риском развития «цитокинового шторма» на фоне COVID-19 и гиперферритинемии. Пульмонология. 2020; 30 (5): 587-598. DOI: 10.18093/0869-0189-2020-30-5-587-598

163. Maksimov V.A., Tkacheva O.N., Strazhesko I.D., Torshin I.Yu., Gromova O.A., Chuchalin A.G., Lazebnik L.B. Human placenta hydrolysate as a drug to reduces markers of inflammation in patients with severe COVID-19. Therapy. 2020; 5: 56-68. (In Russ.) Doi: 10.18565/therapy.2020.5.56-68@@ МаксимовВ.А., ТкачеваО.Н., СтражескоИ.Д., ТоршинИ.Ю., ГромоваО.А., ЧучалинА.Г., ЛазебникЛ.Б.. Гидролизат плаценты человека как препарат, способствующий снижению уровня маркеров воспаления у больных с тяжелыми формами COVID-19. Терапия. 2020; 5: 56-68. Doi: 10.18565/therapy.2020.5.56-68

164. Hoffmann M., Kleine-Weber H., Schroeder S. et al. SARSCoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020. Vol. 181, pp. 271-280. DOI: 10.1016/j.cell.2020.02.052

165. Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020. Vol. 5, pp. 562-569

166. Lin L., Jiang X., Zhang Z. at al. Gastrointestinal Symptoms of 95 Cases With SARS-CoV-2 Infection. Gut. 2020;69(6):997-1001. doi: 10.1136/ gutjnl-2020-321013

167. Madan JC, Koestle DC, Stanton BA, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio. 2012 Aug 21;3(4):e00251-12. doi: 10.1128/mBio.00251-12. PMID: 22911969; PMCID: PMC3428694.

168. Huang Y, Mao K, Chen X, et al. S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense. Science. 2018;359:114-119.

169. Trompette A, Gollwitzer ES, Yadava K, et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014;20:159-166.

170. McAleer JP, Kolls JK. Contributions of the intestinal microbiome in lung immunity. Eur J Immunol. 2018;48:39-49

171. Enaud R, Prevel R, Ciarlo E, Beaufils F, Wieërs G, Guery B, Delhaes L. The Gut-Lung Axis in Health and Respiratory Diseases: A Place for Inter-Organ and InterKingdom Crosstalks. Front Cell Infect Microbiol. 2020 Feb 19;10:9. doi: 10.3389/fcimb.2020.00009.

172. Wang J, Li F, Wei H, et al. . Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation. J Exp Med. 2014;211:2397-2410

173. Bingula R, Filaire M, Radosevic-Robin N, et al. Desired turbulence? Gut-lung axis, immunity, and lung cancer. J Oncol. 2017;2017:5035371

174. Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015;6:1085.

175. Huffnagle GB. The Microbiota and Allergies/Asthma What Is the Evidence Linking Changes in the Microbiota to the Development of Allergic Disease? www.plospathogens.org

176. Verdecchia P, Cavallini C, Spanevello A, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med. 2020 Jun;76:14-20. doi: 10.1016/j.ejim.2020.04.037. Epub 2020 Apr 20. PMID: 32336612; PMCID: PMC7167588.

177. Hashimoto T, Perlot T, Rehman A, et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature. 2012;487:477-481.

178. Effenberger M, Grabherr F, Mayr L, et al. Faecal calprotectin indicates intestinal inflammation in COVID-19. Gut. 2020. doi: 10.1136/gutjnl-2020-321388.

179. Estes M. K. G., Knipe D. M., Howley P. M. et al. Rotaviruses, in Fields Virology (Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013), 6th ed., pp. 1347-1401.

180. Zang R., Gomez Castro M. F., McCune B.T. et al. TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes. Sci Immunol. 2020;5(47): eabc3582. doi:10.1126/sciimmunol.abc3582

181. Marild K., Fredlund H., Ludvigsson J. F. Increased risk of hospital admission for infl uenza in patients with celiac disease: a nationwide cohort study in Sweden. The American journal of gastroenterology. 2010;105(11):2465-2473

182. Di Sabatino A. Is it worth investigating splenic function in patients with celiac disease? World journal of gastroenterology: WJG. 2013; 19(15): 2313

183. Altamimi E. Effect of COVID-19 Pandemic and Lockdown on Children With Gastrointestinal Disorders. Gastroenterology Research. 2020 Jun;13(3):125-128. doi: 10.14740/gr1290. Epub 2020 May 8. PMID: 32655731; PMCID: PMC7331857.

184. Al-Toma A., Volta U., Auricchio R. et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders. United European Gastroenterol J. 2019;7(5):583-613. doi: 10.1177/2050640619844125

185. Lazebnik L.B., Tkachenko E.I., Oreshko LS, et al. Guidelines for diagnosis and treatment of celiac disease. Eksp Klin Gastroenterol. 2015;(5):3-12. (In Russ.) PMID: 26387169.@@ Лазебник Л. Б., Ткаченко Е. И., Орешко Л. С. и др. рекомендации по диагностике и лечению целиакии взрослых Экспериментальная и клиническая гастроэнтерология - 2015. - № 117 (5). - Р. 3-12.

186. Siniscalchi M. et al. COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine. Digestive and Liver Disease. 2020 Oct;52(10):1071-1075. doi: 10.1016/j.dld.2020.05.014. Epub 2020 May 16. PMID: 32425731; PMCID: PMC7229921.

187. Anne Roland Lee. Telehealth Counseling for Patients with Celiac Disease During COVID-19. Gastroint Hepatol Dig Dis. 2020; 3(1): 1-2. DOI: 10.33425/2639-9334.1044

188. Clinical guidelines Crohn's disease. Year of approval: 2020 ID: KR176/1. Scientific and Practical Council of the Ministry of Health of the Russian Federation Publ. Avaible: http://cr.rosminzdrav.ru/#!/recomend/151 (In Russ.)@@ Клинические рекомендации Болезнь Крона Год утверждения: 2020 ID:КР176/1 http://cr.rosminzdrav.ru/#!/recomend/151

189. Goldstein J. L., Eisen G. M., Lewis B. et al. Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopy. Aliment Pharmacol Ther. 2007 May 15;25(10):1211-22. doi: 10.1111/j.1365-2036.2007.03312.x. PMID: 17451567.

190. Washio E., Esaki M., Maehata Y. et al. Proton Pump Inhibitors Increase Incidence of Nonsteroidal AntiInflammatory Drug-Induced Small Bowel Injury: A Randomized, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2016;14(6):809-15.

191. Watanabe T., Takeuchi T., Handa O. et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose rebamipide treatment for low-dose aspirin-induced moderate to severe small intestinal damage. PLoS One. 2015;10(4): e0122330.

192. Zhang S., Qing Q., Bai Y. et al. Rebamipide helps defend against nonsteroidal anti-infl ammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013;58(7):991-2000.

193. Massironi S., Viganò C., Dioscoridi L., et al. Endoscopic findings in patients infected with 2019 novel coronavirus in Lombardy, Italy. Clin Gastroenterol Hepatol. 2020 May 29: S1542-3565(20)30752-7. doi: 10.1016/j. cgh.2020.05.045.

194. Dhar D., Mohanty A. Gut microbiota and Covid-19- possible link and implications. Virus Res. 2020 Aug;285:198018. doi: 10.1016/j.virusres.2020.198018.

195. Toskes P. Bacterial overgrowth of the gastrointestinal tract. Adv.Int. Med. 1993, Vol. 38, pp. 387-407.

196. Maev I. V., Kucheryavyy Yu. A., Andreev D. N., Ivashkina N. Yu. Small bowel bacterial overgrowth syndrome: clinical relevance, criteria of diagnostics and therapeutic management. Infectious diseases: News, Opinions, Training. 2016, no. 3, pp. 118-125. (In Russ.)@@ Маев И. В., Кучерявый Ю. А., Андреев Д. Н., Ивашкина Н. Ю. Синдром избыточного бактериального роста в тонкой кишке: клиническое значение, критерии диагностики и терапевтическая тактика. Инфекционные болезни: новости, мнения, обучение. - 2016. - № 3. - С. 118-125.

197. Lauritano E. C., Gabrielli M., Lupascu A. et al. Rifaximin dosefi nding study for the treatment of small intestinal bacterial overgrowth. Aliment. Pharmacol. Ther. 2005;22;31-35.

198. Cuoco L., Salvagnini M. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin. Minerva Gastroenterol. Dietol. 2006, Vol. 52, pp. 89-95.

199. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology. 2020 May;158(6):1831-1833.e3. doi: 10.1053/j.gastro.2020.02.055.

200. Pan L., Mu M., Ren H. G., et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620. PMID: 32287140; PMCID: PMC7172492.

201. IvashkinV. T., ShelyginYu. A., BaranskayaY. K., et al. Diagnosis and treatment of the irritable bowel syndrome: clinical guidelines of the Russian gastroenterological association and Russian association of coloproctology. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):76-93. (In Russ.) doi: 10.22416/1382-4376-2017-27-5-76-93@@ Ивашкин В. Т. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации и Ассоциации колопроктологов России по диагностике и лечению синдрома раздраженного кишечника. Рос журн гастроэнтерол гепатол колопроктол. - 2017. - Т. 27(5). - С. 76-93. DOI: 10.22416/1382-4376-2017-27-5-76-93

202. Camilleri M., Oduyebo I., Halawi H. Chemical and molecular factors in irritable bowel syndrome: current knowledge, challenges, and unansweredquestions. Am J PhysiolGastrointest Liver Physiol. 2016;311(5):777-784. doi: 10,.1152/ajpgi.00242.2016

203. Ng Q. X., Soh A. Y. S., Loke W., Lim D. Y., Yeo W. S. Th e role of infl ammation inirritable bowel syndrome (IBS). J Infl amm Res.2018;11:345 doi:10.214/JIR.S174982

204. Samsonov A. A., Andreev D. N., Dicheva D. T. Irritable bowel syndrome from the point of view of modern gastroenterology. Farmateka. 2014;18 (291):7-14. (In Russ.)@@ Самсонов А. А., Андреев Д. Н., Дичева Д. Т. Синдром раздраженного кишечника с позиций современной гастроэнтерологии. Фарматека.2014;(18):7-14.

205. Stepanov Yu. M. et al. Determination of intercellular contacts in patients with irritable bowel syndrome. Gastroenterologìa. 2019;53(2):128-131. doi: 10.22141/2308-2097.53.2.2019.168987

206. Fukui H.: Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Infl uence the Risk of Infl ammation? Infl amm Intest Dis. 2016;1:135- 145. doi: 10.1159/000447252

207. Wang C, Pan R, Wan X, et al. Immediate Psychological Responses and Associated Factors during the Initial Stage of the 2019 Coronavirus Disease (COVID-19) Epidemic among the General Population in China. Int J Environ Res Public Health. 2020;17(5):1729. Published 2020 Mar 6. doi:10.3390/ijerph17051729

208. Naito Y., Yoshikawa T. Rebamipide: a gastrointestinal protective drug with pleiotropic activities. Expert Rev Gastroenterol Hepatol. 2010;4(3):261-70. DOI:10.1586/egh.10.25.38-41

209. Zhou Q., Verne M. L., Fields J. Z. et al. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome. Gut. 2019;68(6):996-1002.

210. Song D. U., Ryu M. H., Chay K. O. et al. Eff ect of rebamipide on the glycosaminoglycan content of the ulcerated rat stomach. Fundam Clin Pharmacol. 1998;12(5):546-52.

211. Suzuki T., Yoshida N., Nakabe N. et al. Prophylactic eff ect of rebamipide on aspirin-induced gastric lesions and disruption of tight junctional protein zonula occludens-1 distribution. J Pharmacol Sci. 2008;106(3):469-77.

212. Parfenov A.I., Bykova S.V., Sabelnikova E.A. et al. Enteropathy with impaired membrane digestion and rebamipide. Consilium Medicum. 2019; 21 (8): 49-57. (In Russ.) DOI: 10.26442/20751753.2019.8.190504@@ Парфенов А. И., Быкова С. В., Сабельникова Е. А. идр. Энтеропатия с нарушенным перевариванием мембран и ребамипидом. Консилиум Медикум. -2019. - Т. 21 (8). -С. 49-57. DOI: 10.26442 / 20751753.2019.8.190504

213. Leech B., Schloss J., Steel A. Treatment Interventions for the Management of Intestinal Permeability: A CrossSectional Survey of Complementary and Integrative Medicine Practitioners. J Altern Complement Med. 2019;25(6):623-636.

214. Leech B., McIntyre E., Steel A., Sibbritt D. Risk factors associated with intestinal permeability in an adult population: A systematic review. Int J Clin Pract. 2019. Jun 26: e13385. doi: 10.1111/ijcp.13385

215. Danne P.D., Mignon M. Efficacité comparée du citrate d’alvérine (nouvelle formule) et de la mébévérine chez les adultes atteints de troubles fonctionnels intestinaux. Le Concours Médical. 1996, supplement to no.36-37: I-VIII.

216. Barthet M. et al Efficacité de l’association citrate d’alvérine+siméthicone dans le traitement du syndrome de l’intestin irritable. Act. Med. Int. Gastroenterol. 1996, 10: S1-S7.

217. Ducrotte P, Grimaud JC, Dapoigny M, Personnic S, O'Mahony V, Andro-Delestrain MC. On-demand treatment with alverine citrate/simeticone compared with standard treatments for irritable bowel syndrome: results of a randomised pragmatic study. Int J Clin Pract. 2014;68(2):245-254. doi:10.1111/ijcp.12333

218. Menees S. B., Maneerattannaporn M., Kim H. M., Chey W. D. The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and metaanalysis. Am J Gastroenterol. 2012 Jan; 107(1):28-35.

219. Anand S., Mande S. S. Diet, Microbiota and Gut-Lung Connection. Front Microbiol. 2018;(9):2147. doi: 10.3389/ fmicb.2018.02147.

220. AlFaleh K, Anabrees J. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2014;(4):CD005496. doi: 10.1002/14651858.CD005496.pub4. PubMed PMID: 24723255.

221. Lorenzo-Zúñiga V, Llop E, Suárez C, Alvarez B, Abreu L, Espadaler J, Serra J. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol. 2014;20(26):8709-8716. doi: 10.3748/wjg.v20.i26.8709

222. Openshaw P. J. Crossing barriers: infections of the lung and the gut. Mucosal Immunol. 2009 Mar;2(2):100-102. doi: 10.1038/mi.2008.79

223. Surawicz CM., Brandt LJ., Binion DG., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-98; quiz 499.

224. Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St Sauver JL, Harmsen WS, Zinsmeister AR. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol. 2012;107:89-95.

225. Tian CF, Su BY, Li YJ, Tong YH, Zhao XH, Liang JY, Li SB, Gao BL. Management of antibiotic-associated pseudomembranous colitis in Non-hospitalized and hospitalized patients. Pak J Pharm Sci. 2016;29:1805-1810.

226. Zhang Y, Sun J, Zhang J, Liu Y, Guo L. Enzyme Inhibitor Antibiotics and Antibiotic-Associated Diarrhea in Critically Ill Patients. Med Sci Monit. 2018;24:8781-8788

227. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med. 2002;346:334-339.

228. Högenauer C, Hammer HF, Krejs GJ, Reisinger EC. Mechanisms and management of antibiotic-associated diarrhea. Clin Infect Dis. 1998;27:702-7.

229. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ. 2002;324:1361.

230. Issa I, Moucari R. Probiotics for antibiotic-associated diarrhea: do we have a verdict? World J Gastroenterol. 2014;20:17788-17795.

231. Ruiter-Ligeti J, Vincent S, Czuzoj-Shulman N, Abenhaim HA. Risk Factors, Incidence, and Morbidity Associated With Obstetric Clostridium difficile Infection. Obstet Gynecol. 2018;131:387-391

232. McFarland LV, Ozen M, Dinleyici EC, Goh S. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World J Gastroenterol. 2016;22:3078-3104.

233. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 2008;3:563-578.

234. Zhou H, Xu Q, Liu Yu, Guo LT. Risk factors, incidence, and morbidity associated with antibiotic-associated diarrhea in intensive care unit patients receiving antibiotic monotherapy. World J Clin Cases. 2020 May 26; 8(10): 1908-1915. Published online 2020 May 26. doi: 10.12998/wjcc.v8.i10.1908.

235. Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-98.

236. Puri BK, Hakkarainen-Smith JS, Monro JA. The potential use of cholestyramine to reduce the risk of developing Clostridium difficile-associated diarrhoea in patients receiving long-term intravenous ceftriaxone. Med Hypotheses. 2015;84:78-80.

237. Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35:1355-1369.

238. Shen NT, Maw A, Tmanova LL, et al. Timely Use of Probiotics in Hospitalized Adults Prevents Clostridium difficile Infection: A Systematic Review With Meta-Regression Analysis. Gastroenterology. 2017;152:1889-1900.e9.

239. Evans CT, Safdar N. Current Trends in the Epidemiology and Outcomes of Clostridium difficile Infection. Clin Infect Dis. 2015;60 Suppl 2:S66-S71.

240. Huang H, Wu S, Wang M et al., Nord CE. Molecular and clinical characteristics of Clostridium difficile infection in a University Hospital in Shanghai, China. Clin Infect Dis. 2008;47:1606-1608.

241. Xie C, Li J, Wang K, Li Q, Chen D. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med Infect Dis. 2015;13:128-134.

242. Ma H, Zhang L, Zhang Y, Liu Y, He Y, Guo L. Combined administration of antibiotics increases the incidence of antibiotic-associated diarrhea in critically ill patients. Infect Drug Resist. 2019;12:1047-1054.

243. Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, Talmor D. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med. 2010;170:784-790.

244. Post-COVID-19 global health strategies: the need for an interdisciplinary approach. Aging Clin Exp Res. 2020 Jun 11 : 1-8. doi: 10.1007/s40520-020-01616-x [Epub ahead of print]. Gemelli Against COVID-19 Post-Acute Care Study Group

245. Nikolaou E., Kamilari E., Savkov D. et al. Intestinal microbiome analysis demonstrates azithromycin post-treatment eff ects improve when combined with lactulose. World J Pediatr. 2020;16(2):168-176. doi: 10.1007/s12519-019-00315-6

246. Pinto-Cardoso S., Klatt N. R., Reyes-Terán G. Impact of antiretroviral drugs on the microbiome: unknown answers to important questions. CurrOpin HIV AIDS. 2018;13(1):53-60. doi: 10.1097/COH.0000000000000428

247. Gao J., Gillilland M. G.-3rd, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes. 2014;5(4):571-575. doi: 10.4161/gmic.32130

248. Jang H., Park S., Lee J. et al. Rebamipide alleviates radiation-induced colitis through improvement of goblet cell differentiation in mice. J Gastroenterol Hepatol. 2018;33(4):878-886. doi:10.1111/jgh.14021

249. Parfenov AI, Ruchkina IN, Ataullakhanov RI, Belaia OF, Chikunova BZ, Pichugin AV, Kozhemiakina ESh. Postinfection irritable bowel syndrome. Ter Arkh. 2009;81(2): 39-45. (In Russ.)@@ Парфенов А. И., Ручкина И. Н., Атауллаханов Р. И., Белая О. Ф., Чикунова Б. З., Пичугин А. В., Кожемякина Е. Ш. Постинфекционный синдром раздраженного кишечника. Терапевтический архив 2009; 81(2): 39-45.

250. Magro F , Rahier J-F, Abreu C, et al. Inflammatory Bowel Disease Management During the COVID-19 Outbreak: The Ten Do's and Don'ts from the ECCO-COVID Taskforce. J Crohns Colitis. 2020 Oct 21;14(Supplement_3):S798-S806. doi: 10.1093/ecco-jcc/jjaa160. PMID: 32722754; PMCID: PMC7454472.

251. Clinical guidelines Ulcerative colitis: 2020 ID: KR169. Scientific and Practical Council of the Ministry of Health of the Russian Federation Publ. Moscow. 2020. Available: http://cr.rosminzdrav.ru/#!/recomend/169 (In Russ.)@@ Клинические рекомендации Язвенный колит: 2020 ID:КР169 http://cr.rosminzdrav.ru/#!/recomend/169

252. Rahier J. F., Magro F., Abreu C. et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;(8):443-468.

253. Al-Ani A. H., Prentice R. E., Rentsch C. A. et al. Review article: prevention, diagnosis and management of COVID-19 in the IBD patient. Aliment Pharmacol Ther. 2020 Apr 29:10.1111/apt.15779. Doi: 10.1111/apt.15779

254. Current Data | Secure-IBD Database. https://covidibd. org/current-data/. Accessed June, 20, 2020

255. Wang D , Hu B , Hu C , et al . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021 Mar 16;325(11):1113. PMID: 32031570; PMCID: PMC7042881.

256. Buscarini E, Manfredi G, Brambili G, Menozzi F, Londoni C, et al. GI symptoms as early signs of COVID-19 in hospitalised Italian patients. Gut, 2020 Aug;69(8):1547-1548.doi: 10.1136/gutjnl-2020-321434

257. Samanta J., Dhar J., Khaliq A., Kochhar R. 2019 Novel Coronavirus Infection: Gastrointestinal Manifestations. Journal of Digestive Endoscopy. 2020;11(01):13-18. DOI: 10.1055/s-0040-1712077

258. Jena A, Kumar-M P, Singh AK, Sharma V. Fecal calprotectin levels in COVID-19: Lessons from a systematic review on its use in inflammatory bowel disease during the pandemic. Dig Liver Dis. 2020 Oct 19:S1590-8658(20)30975-0. doi: 10.1016/j.dld.2020.10.021

259. Kennedy N. A., Jones G. R., Lamb C. A., et al. British Society of Gastroenterology guidance for management of infl ammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984-990. doi:10.1136/gutjnl-2020-321244

260. Rubin D. T., Abreu M. T., Rai V., Siegel C. A. On behalf of the International Organization for the Study of Infl ammatory Bowel Disease, Management of Patients with Crohn’s Disease and Ulcerative Colitis During the COVID-19 Pandemic: Results of an International Meeting. Gastroenterology. - 2020, doi: 10.1053/j.gastro.2020.04.002.

261. Gastroenterology professional society guidance on endoscopic procedures during the COVID-19 pandemic American Gastroenterological Association. https://gastro.org/practice-guidance/practice-updates/covid-19/ gastroenterology-professional-society-guidance-on-endoscopic-procedures-during-the-covid-19-pandemic/ Accessed June 06, 2020.

262. RAND PANEL STATEMENTS Patients with COVID-19 Crohn’s Disease and COVID-19 Ulcerative Colitis. IOIBD Update on COVID19 for Patients with Crohn’s Disease and Ulcerative Colitis https://ioibd.org/wp-content/uploads/2020/05/RAND-PANELSTATEMENTS.pdf. Accessed June 06, 2020.

263. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020. doi: 10.1053/j.gastro.2020.05.032

264. Ungaro RC, Brenner EJ, Gearry RB, et al. Effect of IBD medications on COVID-19 outcomes:results from an international registry. Gut. 2021 Apr;70(4):725-732. doi: 10.1136/gutjnl-2020-322539. Epub 2020 Oct 20. PMID: 33082265.

265. Ni YN, Chen G, Sun J, et al. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Crit Care. 2019;23:99.

266. Arabi YM, Mandourah Y, Al-Hameed F; Saudi Critical Care Trial Group. Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome. Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767. doi: 10.1164/rccm.201706-1172OC. PMID: 29161116.

267. Yang Z, Liu J, Zhou Y, et al. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect. 2020 Jul;81(1):e13-e20. doi: 10.1016/j.jinf.2020.03.062. Epub 2020 Apr 10. PMID: 32283144; PMCID: PMC7195158.

268. O’Connor A, Qasim A, O’Moráin CA. The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease. Ther Adv Chronic Dis. 2010;1:7-16.

269. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385-1397.e10.

270. Mehta AK, Gracias DT, Croft M. TNF activity and T cells. Cytokine. 2018;101:14-18.

271. Tursi A, Angarano G, Monno L, et al. COVID-19 infection in Crohn’s disease under treatment with adalimumab. Gut. 2020;69:1364-1365.

272. Anon. Chinese Clinical Trial Register (ChiCTR) - The World Health Organization International Clinical Trials Registered Organization Registered Platform http://www.chictr.org.cn/showprojen.aspx?proj=49889. Accessed May 9, 2020

273. Sneller MC, Clarridge KE, Seamon C, et al. An open-label phase 1 clinical trial of the anti-α4β7 monoclonal antibody vedolizumab in HIV-infected individuals. Sci Transl Med. 2019;11.

274. Sandborn WJ, Ghosh S, Panes J, et al. Study A3921063 Investigators Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367:616-624.

275. Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib. J Microbiol Immunol Infect. 2020;53:368-370

276. Mao R, Liang J, Shen J, et al. Chinese Society of IBD, Chinese Elite IBD Union; Chinese IBD Quality Care Evaluation Center Committee Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol. 2020;5:425-427

277. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol. 2006;101:812-822. doi: 10.1111/j.1572-0241.2006.00465.x

278. McFarland LV. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J. Gastroenterol. 2010;16:2202-2222. doi: 10.3748/wjg.v16.i18.2202.

279. IvashkinVT, MayevIV, ShifrinOS, et al. Clinical Recommendations of the Russian Gastroenterological Association for the diagnosis and treatment of chronic pancreatitis. Moscow, 2014. 45p. (in Russ.)@@ Клинические Рекомендации Российской Гастроэнтерологической Ассоциации по диагностике и лечению хронического панкреатита / Под ред. Ивашкина В. Т., Маева И. В., Шифрина О. С. и др. - М., 2014. -45с.

280. Zaratyants O.V., Samsonova M.V., Mikhaleva L.M., Chernyaev A.L., Mishnev O.D .. Krupnov N.M., Kalinin D.V. Pathological anatomy of COVID-19: Atlas. Moscow, GBU "NII OZMM DZM" Publ., 2020, 140 p. (In Russ.)@@ Патологическая анатомия COVID-19: Атлас/ Заратьянц О.В., Самсонова М.В., Михалева Л.М., Черняев А.Л., Мишнев О.Д.. Крупнов Н.М., Калинин Д.В. Под общей редакцией Заратьянца О.В. - Москва, ГБУ «НИИ ОЗММ ДЗМ», 2020 - 140 с.

281. Maev I.V., Shpektor A.V., Vasilyeva E.Y., et al. Novel coronavirus infection COVID-19: extrapulmonary manifestations. Terapevticheskii arkhiv. 2020, Vol. 92, No. 8, pp. 4-11. (In Russ.) doi: 10.26442/00403660.2020.08.000767@@ Маев И.В., Шпектер А.В., Васильева Е.Ю., Манчуров В.Н., Андреев Д.Н. Новая коронавирусная инфекция COVID-19: экстрапульмональные проявления // Терапевтический архив. - 2020, № 8. - С.5-12

282. Kumaran N.K. et al. Coronavirus disease-19 (COVID-19) associated with acute necrotising pancreatitis (ANP). BMJ. Case Rep. 2020: e237903. doi: 10.1136/bcr-2020-237903

283. Szatmary P., Arora A., Raraty M. G. T. et al. Emerging phenotype of SARS-CoV2 associated pancreatitis., Gastroenterology. 2020 Oct;159(4):1551-1554. doi: 10.1053/j.gastro.2020.05.069. Epub 2020 Jun 1. PMID: 32497545; PMCID: PMC7263253.

284. Bruno G., Fabrizio C., Santoro C. R., Buccoliero G. B. Pancreatic injury in the course of coronavirus disease 2019 (COVID-19): a not-so-rare occurrence [published online ahead of print, 2020 Jun 4]. J Med Virol. 2020;10.1002/jmv.26134. doi:10.1002/jmv.26134

285. Drapkina O. M., Maev I. V., Bakulin I. G. et al. Temporary guidelines. Diseases of the digestive system in the context of the novel coronavirus infection (COVID-19) pandemic. Moscow, 2020. 68 p. (in Russ.)@@ Временные методические рекомендации. Болезни органов пищеварения в условиях пандемии новой коронавирусной инфекции (COVID-19) // Драпкина О. М., Маев И. В., Бакулин И. Г. и др. - Москва, 2020. - 68 с.

286. Scientific Society of Gastroenterologists. Recommendations of the Scientific Society of Gastroenterologists for the diagnosis and treatment of chronic pancreatitis (adopted by the II Congress of the NOGR on March 2, 2011 at the meeting of the Russian Pancreatological Club. Experimentaland Clinical Medicine. 2011;(7): 122-129. (in Russ.)@@ Рекомендации Научного Общества Гастроэнтерологов по диагностике и лечению хронического панкреатита (приняты IIсъездом НОГР 2 марта 2011 на заседании Российского панкреатологического клуба// Экспериментальная и клиническая медицина. - 2011. - № 7. - С. 122-129.

287. Khatkov IE, Maev IV, Abdulkhakov SR, et al. Th e Russian consensus on the diagnosis and treatment of chronic pancreatitis. Therapeutic archive = Terapevticheskiy arkhiv. 2017;89(2):105-113. (in Russ.) Doi:10.17116/ terarkh2017892105-113@@ Российский консенсус по диагностике и лечению хронического панкреатита. / Хатьков И. Е., Маев И. В., Абдулхаков С. Р. и соавт.// Терапевтический архив. - 2017. - № 2. - С. 105-113. doi: 10. 17116/terarkh 2017 892105-113

288. Khat'kov I. E., Maev I. V., Bordin D. S., Kucheryavyy Yu. A., Grinevich V. B. The Russian consensus on diagnosis and treatment of chronic pancreatitis: points of debate. Almanac of Clinical Medicine. 2016;44(6):654-660. (In Russ.) doi: 10.18786/2072-0505-2016-44-6654-660@@ Хатьков И. Е. Спорные вопросы российского консенсуса по диагностике и лечению хронического панкреатита. / Хатьков И. Е., Маев И. В., Бордин Д. С., Кучерявый Ю. А., Гриневич В. Б. //Альманах клинической медицины. - 2016. -Т. 44., № 6. - С. 654-660.

289. IvashkinV. T., MayevI. V., OkhlobystinA. V., et al. Diagnostics and treatment of pancreatic exocrine insuffi ciency: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):72-100. (In Russ.) doi:10.22416/1382-4376-2018-28-272-100@@ Ивашкин В. Т., Маев И. В., Охлобыстин А. В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению экзокринной недостаточности поджелудочной железы. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(2):72-100.

290. KhatkovI. E., MayevI. V., BordinD. S., et al. Russian consensus on the diagnosis and treatment of chronic pancreatitis: focus on nutritional status and problems of nutrition. Farmateka. 2016;s5-16:27-32. (in Russ.)@@ Хатьков И. Е. Российский консенсус по диагностике и лечению хронического панкреатита: акцент на нутритивный статус и вопросы питания. / Хатьков И. Е., Маев И. В., Бордин Д. С., Кучерявый Ю. А. и соавт.// Фарматека. - 2016; Гастроэнтерология/гепатология. - С. 27-32.

291. Clinical Recommendations of the Russian Society of Surgeons, the Association of Hepatopancreatobiliary Surgeons of the CIS countries “Acute Pancreatitis”. Moscow, 2015. 38 p. (in Russ.)@@ Клинические Рекомендации Российского Общества Хирургов, Ассоциации гепатопанкреатобилиарных хирургов стран СНГ «Острый панкреатит» - М., 2015. - 38 с.

292. Dedov I. I., Shestakova M. V., Mayrov A. Yu. Clinical Recommendations of the Russian Association of Endocrinologists “Algorithms of Specialized Medical Care for Patients with Diabetes Mellitus”. Moscow, 2017. 111 P. (in Russ.)@@ Клинические Рекомендации Российской Ассоциации Эндокринологов «Алгоритмы Специализированной Медицинской Помощи больным Сахарным Диабетом» / Под ред. Дедова И. И., Шестаковой М. В., Майрова А. Ю. - М., 2017. - 111 с.

293. Grinev E. N., Halimov Yu. Sh., Babenko A. Yu., et al. Temporary guidelines for the management of patients with COVID-19 and endocrine diseases. Medical Association of Endocrinologists. St. Petersburg, 2020. 9 P. (in Russ.)@@ Временные рекомендации по ведению больных COVID-19 и эндокринными заболеваниями / Под ред. Гринева Е. Н., Халимова Ю. Ш., Бабенко А. Ю. и др. - Медицинской Ассоциацией Эндокринологов Санкт-Петербурга, 2020 г. - 9 с.

294. Ivashkin V. T., Maev I. V., Tsar'kov P. V., et al. Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of peptic ulcer disease in adults. Moscow. 2020. (in Russ.)@@ В. Т. Ивашкин, И. В. Маев, П. В. Царьков и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по Диагностике и лечению язвенной болезни у взрослых. 2020

295. Grinevich V.B., Kravchuk Yu.A., Ped’ V.I., Rodionov G.G., Shantyr’ I.I., Kuvakin V.I., Svetkina E.V., Arapkhanovа M.M., Medvedko S.A. Clinical efficacy of Meteospasmyl in treatment of painful abdominal and dyspeptic syndromes in patients with chronic pancreatitis. Medical alphabet. 2019;2(13):5-12. (In Russ.) doi: 10.33667/2078-5631-2019-2-13(388)-5-12@@ Гриневич В.Б., Кравчук Ю.А., Педь В.И. и др. Клиническая эффективность Метеоспазмила в комплексной терапии болевого абдоминального и диспептического синдромов у пациентов с хроническим панкреатитом. Медицинский алфавит. 2019;2(13):5-12. https://doi.org/10.33667/2078-5631-2019-2-13(388)-5-12

296. Ivashkin V. T., Sheptulin A. A., Zolnikova O. Yu., Okhlobystin A. V., Poluektova E. A., Trukhmanov A. S., Shirokova E. N., Gonik M. I., Trofimivskaya N. I. New Coronavirus Infection (COVID-19) and Digestive System. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(3):7-13. (In Russ.) doi: 10.22416/1382-4376-2020-30-3-7@@ Ивашкин В. Т., Шептулин А. А., Зольникова О. Ю. и др. Новая коронавирусная инфекция (COVID-19) и система органов пищеварения // Российский журнал гастроэнтерологии, гепатологии и колопроктологии 2020 30(2) - 7. Doi: 10.22416/1382- 4371 2020-30-3-7.

297. Chung M., Bernheim A., Mei X. et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). Radiology. 2020;295 (1):202-207. Doi: 10.1148/radio l.2020200230

298. Huang G., Gong T., Wang G. et al. Timely Diagnosis and Treatment Shortens the Time to Resolution of Coronavirus Disease (COVID-19) Pneumonia and Lowers the Highest and Last CT Scores From Sequential Chest CT. AJR Am J Roentgenol. 2020 Aug;215(2):367-373. doi: 10.2214/AJR.20.23078. Epub 2020 Mar 30. PMID: 32223665.

299. Poggiali E., Dacrema A., Bastoni D. et al. Can lung US help critical care clinicians in the early diagnosis of novel coronavirus (COVID-19) pneumonia? Radiology. 2020;13:200847

300. Bangash M.N., Patel J., Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol. Hepatol. 2020 Jun;5(6):529-530. doi: 10.1016/S2468-1253(20)30084-4. Epub 2020 Mar 20. PMID: 32203680; PMCID: PMC7270582.

301. Richardson S., Hirsch J.S., Narasimhan M. et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775. Erratum in: JAMA. 2020 May 26;323(20):2098. PMID: 32320003; PMCID: PMC7177629.

302. Dane B, Brusca-Augello G., Kim D., Katz D.S. Unexpected Findings of Coronavirus Disease (COVID-19) at the Lung Bases on Abdominopelvic CT. AJR Am J Roentgenol. 2020 Sep;215(3):603-606. doi: 10.2214/AJR.20.23240. Epub 2020 Apr 22. PMID: 32319792.

303. Vano E, Frija G., Stiller W. et al. Harmonisation of imaging dosimetry in clinical practice: practical approaches and guidance from the ESR EuroSafe Imaging initiative. Insights Imaging. 2020 Mar 30;11(1):54. doi: 10.1186/s13244-020-00859-6. PMID: 32232684; PMCID: PMC7105556.

304. ACR recommendations for the use of Chest Radiography and Computed Tomography (CT) for Suspected COVID-19 Infection.https://www.acr.org/Advocacy-and-Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CTfor-Suspected-COVID19-Infection. Accessed on 4.16.2020

305. Paulo G., Damilakis J., Tsapaki V. et al. Diagnostic Reference Levels based on clinical indications in computed tomography: a literature review. Insights Imaging. 2020 Aug 17;11(1):96. doi: 10.1186/s13244-020-00899-y. PMID: 32804275; PMCID: PMC7431477.

306. Pan L, Mu M., Yang P. et al. Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study. Am J Gastroenterol. 2020 May;115(5):766-773. doi: 10.14309/ajg.0000000000000620. PMID: 32287140; PMCID: PMC7172492.

307. Chen A., Agarwal A., Ravindran N. et al. Are Gastrointestinal Symptoms Specific for Coronavirus 2019 Infection? A Prospective Case-Control Study From the United States. Gastroenterology. 2020 Sep;159(3):1161-1163.e2. doi: 10.1053/j.gastro.2020.05.036. Epub 2020 May 16. PMID: 32422209; PMCID: PMC7229473.

308. Bhayana R., Som A., Li M.D. et al. Abdominal Imaging Findings in COVID-19: Preliminary Observations. Radiology. 2020 Oct;297(1):E207-E215. doi: 10.1148/radiol.2020201908. Epub 2020 May 11. PMID: 32391742; PMCID: PMC7508000.

309. Fang Y., Zhang H., Xie J. et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology. 2020 Aug;296(2):E115-E117. doi: 10.1148/radiol.2020200432. Epub 2020 Feb 19. PMID: 32073353; PMCID: PMC7233365.

310. Goldberg-Stein S, .Fink A., Paroder V. et al. Abdominopelvic CT findings in patients with novel coronavirus disease 2019 (COVID-19). Abdom Radiol (NY). 2020 Sep;45(9):2613-2623. doi: 10.1007/s00261-020-02669-2. Epub 2020 Aug 6. PMID: 32761402; PMCID: PMC7406871.

311. Cholankeril G., Podboy A., Aivaliotis V.I. et al. High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California. Gastroenterology. 2020 Aug;159(2):775-777. doi: 10.1053/j.gastro.2020.04.008. Epub 2020 Apr 10. PMID: 32283101; PMCID: PMC7194555.

312. Abdelmohsen M.A., Alkandari B.M., Gupta V.K., ElBeheiry A.A. Diagnostic value of abdominal sonography in confirmed COVID-19 intensive care patients. Egypt J Radiol Nucl Med. 51, 198 (2020). Doi:10.1186/s43055-020-00317-9

313. Guo T, Li X, Yang X, et al. Gadoxetic acid-enhanced hepatobiliary-phase magnetic resonance imaging for pyrrolizidine alkaloidinduced hepatic sinusoidal obstruction syndrome and association with liver function. Sci. Rep. 2019; 9:1231.

314. Li X., Yang X., Xu D. et al. Magnetic resonance imaging findingsin patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Clin. Gastroenterol. Hepatol. 2017;15:955-957.

315. Luo S., Zhang X., Xu H. Don’t overlook digestive symptoms in patients with 2019 novel coronavirus disease (COVID-19). Clin. Gastroenterol. Hepatol. 2020 Jun;18(7):1636-1637. doi: 10.1016/j.cgh.2020.03.043. Epub 2020 Mar 20. PMID: 32205220; PMCID: PMC7154217.

316. Nakatis Ya.A., Ratnikov V.A., Kashchenko V.A. et al. Surgical care arrangement at the general hospital during the COVID-19 pandemic. Extreme Medicine. 2020; (4): 91-5. DOI: 10.47183/mes.2020.015

317. Prokop M., van Everdingen W., van Rees Vellinga T. et al. CO-RADS - A categorical CT assessment scheme for patients with suspected COVID-19:definition and evaluation. Radiology. 2020:201473

318. Ratnikova A.K. Additional possibilities of standard computed tomography of the lungs in the study of the organs of the gastrointestinal tract in patients with COVID-19 / Smolensk-Winter-2021. Sat. scientific. thesis. scientific-practical conf. with international participation online. Smolensk, 2021, 10 P. (in Russ.)@@ Ратникова А.К. Дополнительные возможности стандартного компьютерно-томографического исследования легких в изучении органов желудочно-кишечного тракта у больных COVID-19 / Смоленск-Зима-2021. Сб. науч. тез. науч.-практ. конф. с международным участием online. Смоленск, 2021. - с. 10

319. Di Saverio S., Pata F., Gallo G. et al. Coronavirus pandemic and colorectal surgery: practical advice based on the Italian experience. Colorectal Dis. 2020 Jun;22(6):625-634. doi: 10.1111/codi.15056. Epub 2020 Jun 1. PMID: 32233064.

320. Rodriguez-Morales A.J., Cardona-Ospinaa J.A., Gutierrez-Ocampoa E. et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis. 2020 Mar-Apr;34:101623. doi: 10.1016/j.tmaid.2020.101623. Epub 2020 Mar 13. PMID: 32179124; PMCID: PMC7102608.

321. Diaz J. H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020;27(3): taaa041. doi:10.1093/jtm/taaa041

322. Zheng Y. Y., Ma Y. T., Zhang J. Y., Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259-260. doi:10.1038/s41569-020-0360-5

323. Abassi Z., Assady S., Khoury E. E., Heyman S. N. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications. Am J Physiol Heart Circ Physiol. 2020; 318(5): H1080-H1083. doi:10.1152/ ajpheart.00215.2020

324. Vaduganathan M., Vardeny O., Michel T., McMurray J. V, Pfeffer M. A, Solomon S. D. Renin-AngiotensinAldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020;382(17):1653-1659. doi:10.1056/ NEJMsr2005760

325. Gheblawi M., Wang K., Viveiros A., et al. AngiotensinConverting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020;126(10):1456-1474. doi:10.1161/ CIRCRESAHA.120.317015.

326. South A. M., Diz D. I., Chappell M. C. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5): H1084-H1090. doi:10.1152/ajpheart.00217.2020.

327. Ferrario C. M, Jessup J., Chappell M. C. et al. Eff ect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005; 111:2605-10.

328. Burchill L. J, Velkoska E., Dean R.G, Griggs K., Patel S. K., Burrell L. M. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond). 2012; 123: 649-58.

329. Furuhashi M, Moniwa N, Mita T, et al. Urinary angiotensinconverting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015; 28: 15-21.

330. Halliday B. P., Wassall R., Lota A. S., et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019; 393: 61-73.

331. Kerneis M, Ferrante A, Guedeney P, Vicaut E, Montalescot G. Severe acute respiratory syndrome coronavirus 2 and renin-angiotensin system blockers: A review and pooled analysis. Arch Cardiovasc Dis. 2020 Oct 22:S1875-2136(20)30219-9.

332. Ren L, Yu S, Xu W, Overton JL, Chiamvimonvat N, Thai PN. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: A meta-analysis. J Cardiol. 2020 Nov 2:S0914-5087(20)30353-1.

333. Nunes JPL. Mortality and use of angiotensin-converting enzyme inhibitors in COVID 19 disease: a systematic review. Porto Biomed J. 2020 Nov 11;5(6):e085.

334. Martínez-Del Río J, Piqueras-Flores J, Nieto-Sandoval Martín de la Sierra P, Negreira-Caamaño M, Águila-Gordo D, Mateo-Gómez C, Salas-Bravo D, Rodríguez-Martínez M. Comparative analysis between the use of renin-angiotensin system antagonists and clinical outcomes of hospitalized patients with COVID-19 respiratory infection. Med Clin (Engl Ed). 2020 Dec 11;155(11):473-481. doi: 10.1016/j.medcle.2020.07.013. Epub 2020 Nov 12. PMID: 33209988; PMCID: PMC7659923.

335. Yokoyama Y, Aikawa T, Takagi H, Briasoulis A, Kuno T. Association of renin-angiotensin-aldosterone system inhibitors with mortality and testing positive of COVID-19: Meta-analysis. J Med Virol. 2021 Apr;93(4):2084-2089. doi: 10.1002/jmv.26588. Epub 2020 Oct 30. PMID: 33038021; PMCID: PMC7675602.

336. Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, Yang R, Di W, Wang Z, Li Z, Gao H, Liu L, Zhang G. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020 Dec;9(1):757-760.

337. Zhang P., Zhu L., Cai J. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671-1681.

338. Guo X., Zhu Y., Hong Y. Decreased mortality of COVID-19 with renin-angiotensin- aldosterone system inhibitors therapy in patients with hypertension: a meta-analysis. Hypertension. 2020;76:e13-4.

339. Flacco ME, Acuti Martellucci C, Bravi F, Parruti G, Cappadona R, Mascitelli A, Manfredini R, Mantovani LG, Manzoli L. Treatment with ACE inhibitors or ARBs and risk of severe/lethal COVID-19: a meta-analysis. Heart. 2020 Oct;106(19):1519-1524.

340. Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J, Cai J, Yang R, Han J, Huang Y, He S. Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study. Hypertension. 2020 Jul;76(1):51-58.

341. Lim JH, Cho JH, Jeon Y et al. Adverse impact of renin-angiotensin system blockade on the clinical course in hospitalized patients with severe COVID-19: a retrospective cohort study. Sci Rep. 2020 Nov 20;10(1):20250.

342. Hippisley-Cox J, Young D, Coupland C, Channon KM, Tan PS, Harrison DA, Rowan K, Aveyard P, Pavord ID, Watkinson PJ. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020 Oct;106(19):1503-1511

343. Jeffrey K. Aronson, Robin E. Ferner. Drugs and the renin-angiotensin system in covid-19. Clinical effects are unpredictable, so treatment decisions must be tailored and pragmatic. BMJ. 2020;369: m1313 doi: 10.1136/bmj. m1313 (Published 2 April 2020) Page 2

344. Wang T. D. Renin-Angiotensin System Inhibitors and COVID-19: Potential Therapeutics Rather Than Perpetrators. Acta Cardiol Sin. 2020;36(3):179-182. doi:10.6515/ACS.202005_36(3).20200430A.

345. Kuba K., Imai Y., Rao S. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879

346. OganovR. G., SimanenkovV. I., BakulinI. G., et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66. (In Russ.) doi: 10.15829/1728-8800-2019-1-5-66@@ Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Клинические рекомендации. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66. Doi: 10.15829/1728-8800-2019-1-5-66

347. Burnier M., Bakris G., Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? Journal of Hypertension. 2019;(37):1574-1586. DOI:10.1097/HJH.0000000000002088.

348. Zuo T, Zhang F, Lui GCY, Yeoh YK, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Time of Hospitalization. Gastroenterology. 2020 May 19: S0016-5085(20)34701-6. doi: 10.1053/j.gastro.2020.05.048.

349. Gu S, Chen Y, Wu Z, Chen Y, Gao H, Lv L, et al. Alterations of the Gut Microbiota in Patients with COVID-19 or H1N1 Infl uenza. Clin Infect Dis. 2020 Jun 4: ciaa709. doi: 10.1093/cid/ciaa709.

350. Tang L, Gu S, Gong Y, Li B, et al. Clinical signifi cance of the correlation between changes in the major intestinal bacteria species and COVID-19 severity. Engineering. 2020. doi: 10.1016/j.eng.2020.05.013.

351. Archer DL, Kramer DC. Th e Use of Microbial Accessible and Fermentable Carbohydrates and/or Butyrate as Supportive Treatment for Patients With Coronavirus SARS-CoV-2 Infection. Front Med (Lausanne). 2020 Jun 5;7:292. doi: 10.3389/fmed.2020.00292

352. Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010 Oct 15;182(8):1058-64. doi: 10.1164/rccm.200912-1853OC.

353. Zeng J, Wang CT, Zhang FS, Qi F, et al. Eff ect of probiotics on the incidence of ventilator-associated pneumonia in critically ill patients: a randomized controlled multicenter trial. Intensive Care Med. 2016 Jun;42(6):1018-28. doi: 10.1007/s00134-016-4303-x

354. Di Renzo L, Merra G, Esposito E, De Lorenzo A. Are probiotics effective adjuvant therapeutic choice in patients with COVID-19? Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4062-4063. doi: 10.26355/eurrev_202004_20977. PMID: 32374010.

355. Baud D, Dimopoulou Agri V, Gibson GR, Reid G, Giannoni E. Using Probiotics to Flatten the Curve of Coronavirus Disease COVID-2019 Pandemic. Front Public Health. 2020 May 8;8:186. doi: 10.3389/ fpubh.2020.00186

356. Sarkar P, Borah S, Sharma HK. Can microbial SCFA, Butyrate be the alternate Savior against COVID-19?, Curr. Trends Pharm. Res., 2020, 7 (1): 11-14.

357. d’Ettorre G, Ceccarelli G, Marazzato M, et al. Challenges in the Management of SARS-CoV2 Infection: Th e Role of Oral Bacteriotherapy as Complementary Th erapeutic Strategy to Avoid the Progression of COVID-19. Front Med (Lausanne). 2020 Jul 7;7:389. doi: 10.3389/ fmed.2020.00389

358. He LH, Ren LF, Li JF, Wu YN, Li X, Zhang L. Intestinal Flora as a Potential Strategy to Fight SARS-CoV-2 Infection. Front Microbiol. 2020 Jun 9;11:1388. doi: 10.3389/fmicb.2020.01388

359. Saville S., Ouwehand A. Immune Impacts of Probiotics, Prebiotics and Synbiotics. International Probiotics Association (IPA) Education and Communications Committee. Available at: http://internationalprobiotics. org/immune/ [Accessed 10 August 2020].

360. ISAPP board of directors. How some probiotic scientists are working to address COVID-19. Available at: https://isappscience.org/how-some-probiotic-and-prebiotic-scientists-are-working-to-address-covid-19/ [Accessed 10 August 2020].

361. Katie McCallum. Post-COVID Syndrome: What Should You Do If You Have Lingering COVID-19 Symptoms? https://www.houstonmethodist.org/blog/articles/2020/nov/post-covid-syndrome-what-should-you-do-if-you-have-lingering-covid-19-symptoms [Accessed 10 August 2020]

362. Sudre CH, Murray B, Varsavsky T et al. Attributes and predictors of Long-COVID: analysis of COVID cases and their symptoms collected by the Covid Symptoms Study App. Med Rxiv. 2020.10.19.20214494; doi: 10.1101/2020.10.19.20214494

363. Garg P, Arora U, Kumar A, Wig N. The "post-COVID" syndrome: How deep is the damage?. J Med Virol. 2021;93(2):673-674. doi:10.1002/jmv.26465

364. Gavriatopoulou M., Korompoki E., Fotiou D. et al.Organ-specific manifestations of COVID-19 infection. Clin. Exp. Med., 27 (2020), pp. 1-14, 10.1007/s10238-020-00648-x; Horvath L, Lim J.W.J., Taylor J.W. et al. Smell and taste loss in COVID-19 patients: assessment outcomes in a Victorian population. Acta Otolaryngol 2020: 1-5

365. Yong, S.J. Long-Haul COVID-19: Putative Pathophysiology, Risk Factors, and Treatments. Preprints. 2020, 2020120242. doi: 10.20944/preprints202012.0242.v1

366. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis. medRxiv [Preprint]. 2021 Jan 30:2021.01.27.21250617. doi: 10.1101/2021.01.27.21250617. PMID: 33532785; PMCID: PMC7852236.

367. Salabei JK, Fishman TJ, Asnake ZT, Ali A, Iyer UG. COVID-19 Coagulopathy: Current knowledge and guidelines on anticoagulation. Heart Lung. 2021 Jan 20;50(2):357-360. doi: 10.1016/j.hrtlng.2021.01.011. Epub ahead of print. PMID: 33524866; PMCID: PMC7816593.

368. Deidda S, Tora L, Firinu D. et al. Gastrointestinal coronavirus disease 2019: epidemiology, clinical features, pathogenesis, prevention, and management. Expert Rev Gastroenterol Hepatol. 2021 Jan;15(1):41-50. doi: 10.1080/17474124.2020.1821653. Epub 2020 Nov 24. PMID: 32955375.

369. Choi B, Choudhary MC, Regan J. et al. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11. PMID: 33176080; PMCID: PMC7673303.

370. Choi HM, Moon SY, Yang HI, Kim KS. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics. Int J Mol Sci. 2021 Feb 9;22(4):1737. doi: 10.3390/ijms22041737. PMID: 33572274.

371. Hu, F., Chen, F., Ou, Z. et al. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. Cell Mol Immunol. 17, 1119-1125 (2020). Doi: 10.1038/s41423-020-00550-2

372. Pagano N., Laurent-Rolle M., Hsu J.C. et al. Detection of long SARS-CoV-2 nucleocapsid sequences in peripheral blood monocytes collected soon after hospital admission. bioRxiv. 2020.12.16.423113; doi: 10.1101/2020.12.16.423113

373. Boumaza A., Gay L., Mezouar S. et al. Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis. bioRxiv. 2020.09.17.300996; doi: 10.1101/2020.09.17.300996

374. Kopel J, Perisetti A, Gajendran M, et al . Clinical insights into the gastrointestinal manifestations of COVID-19. Dig Dis Sci. 2020;65:1932-9. doi: 10.1007/s10620-020-06362-8

375. van Doorn AS, Meijer B, Frampton CMA, Barclay ML, de Boer NKH. Systematic review with meta-analysis: SARS-CoV-2 stool testing and the potential for faecal-oral transmission. Aliment Pharmacol Ther. 2020 Oct;52(8):1276-1288. doi: 10.1111/apt.16036. Epub 2020 Aug 27. PMID: 32852082; PMCID: PMC7461227.

376. Kumar V. How could we forget immunometabolism in SARS-CoV2 infection or COVID-19? Int Rev Immunol. 2020 Nov 6:1-36. doi: 10.1080/08830185.2020.1840567. Epub ahead of print. PMID: 33155525

377. Wang EY, Mao T, Klein J. et al. Diverse Functional Autoantibodies in Patients with COVID-19. medRxiv. [Preprint]. 2020 Dec 12:2020.12.10.20247205. doi: 10.1101/2020.12.10.20247205. PMID: 33330894; PMCID: PMC7743105.

378. Garvin MR, Alvarez C, Miller JI., et al. A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm. Elife. 2020 Jul 7;9:e59177. doi: 10.7554/eLife.59177. PMID: 32633718; PMCID: PMC7410499.

379. Afrin L B., Weinstock L B., Molderings Gd J. Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome. Int J Infect Dis. 2020 Nov;100:327-332. doi: 10.1016/j.ijid.2020.09.016. Epub 2020 Sep 10. PMID: 32920235; PMCID: PMC7529115.

380. Mönkemüller K, Fry L, Rickes S. COVID-19, coronavirus, SARS-CoV-2 and the small bowel. Rev Esp Enferm Dig. 2020 May;112(5):383-388. doi: 10.17235/reed.2020.7137/2020. PMID: 32343593

381. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260-3. DOI: 10.1126/science.abb2507

382. Lamprecht B. Gibt es ein Post-COVID-Syndrom? [Is there a post-COVID syndrome?]. Pneumologe (Berl). 2020 Oct 8:1-4. (In German.) doi: 10.1007/s10405-020-00347-0. Epub ahead of print. PMID: 33052198; PMCID: PMC7543035.

383. Perrin R, Riste L, Hann M, Walther A, Mukherjee A, Heald A. Into the looking glass: post-viral syndrome post COVID-19. Med Hypotheses. 2020;144:110055. doi: 10.1016/j.mehy.2020.110055

384. Bektas A, Schurman SH, Franceschi C, Ferrucci L. A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging? Immun Ageing. 2020;17:23. doi: 10.1186/s12979-020-00196-8

385. Lopez M, Bell K, Annaswamy T, Juengst S, Ifejika N. COVID-19 guide for the rehabilitation clinician: a review of nonpulmonary manifestations and complications. Am. J. Phys. Med. Rehabil. 2020; 99(8):669-673. doi: 10.1097/PHM.0000000000001479

386. Amenta E.M., Spallone A., Rodriguez-Barradas M.C.et al. Post-Acute COVID-19: An Overview and Approach to Classification. Open Forum Infect. Dis. [Internet] 2020 [cited 2020 Dec 13]; Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7665635/

387. Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al. Post-acute COVID-19 Syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021 Mar;82(3):378-383. doi: 10.1016/j.jinf.2021.01.004. Epub 2021 Jan 12. PMID: 33450302; PMCID: PMC7802523.

388. COVID-19 rapid guideline: managing the long-term effects of COVID-19 NICE guideline [NG188]Published date:18 December 2020] https://www.nice.org.uk/guidance/ng188

389. Vorobyev P., Vorobiev A., Darmodekhina D. Report on postcovid syndrome in the CIS *and other countries with a Russian speaking population. 2020. https://drive.google.com/file/d/1Z9LY72WbuYOtS4zmwQrdXpbXKplHRafU/view

390. Tenforde MW. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998. doi: 10.15585/mmwr.mm6930e1. PMID: 32730238; PMCID: PMC7392393.

391. Carfì A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603-605. doi: 10.1001/jama.2020.12603

392. Hui DS, Joynt GM, Wong KT, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401-409. doi: 10.1136/thx.2004.030205

393. Burnham EL, Hyzy RC, Paine R, 3rd, et al. Chest CT features are associated with poorer quality of life in acute lung injury survivors. Crit. Care Med. 2013;41(2):445-456. doi: 10.1097/CCM.0b013e31826a5062

394. Tang XJ, Chen CC et al. Long-term follow-up of 5 survivors after the first outbreak of human infections with avian influenza A(H7N9) virus in Shanghai, China. Chin Med J. 2016;129:2128-2130. doi: 10.4103/0366-6999.189061

395. Marchiori E, Hochhegger B, Zanetti G. Organising pneumonia as a late abnormality in influenza A (H1N1) virus infection. Br J Radiol. 2012;85:841. doi: 10.1259/bjr/91363092

396. Tian S, Xiong Y, Liu H, Nui L, Guo J, Liao M, Xiao SY. Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies. Mod Pathol. 2020;33:1007-1014. doi: 10.1038/s41379-020-0536-x

397. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. Published online January 8, 2021. Doi: 10.1016/ S0140-6736(20)32656-8

398. Ridruejo E. , Soza A. The liver in times of COVID-19: what hepatologists should know. Ann Hepatol, 19 (2020), pp. 353-358. Doi: 10.1016/j.aohep.2020.05.001

399. Fierro N.A. COVID-19 and the liver: What do we know after six months of the pandemic? Ann Hepatol. 2020 Nov-Dec;19(6):590-591. doi: 10.1016/j.aohep.2020.09.001. Epub 2020 Sep 18. PMID: 32956871; PMCID: PMC7500273.

400. GBD 2017 Cirrhosis Collaborators.The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systemic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol, 5 (2020), pp. 245-266. Doi: 10.1016/S2468-1253(19)30349-8

401. Sonia A. Lozano-Sepulveda, Galan-Huerta K., Martínez-Acuña N. Et al. SARS-CoV-2 another kind of liver aggressor, how does it do that? Annals of Hepatology, Vol. 19, Is. 6, 2020, p. 592-596. Doi: 10.1016/j.aohep.2020.08.062

402. Guan, W. J. Zheng-yi Ni, Hu Yu. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708-1720 (2020)

403. El Moheb M. Gastrointestinal complications in critically ill patients with and without COVID-19. JAMA. 24, e2019400 (2020)

404. Song Y., Liu P., Shi XL. et al. SARS-CoV-2 induced diarrhea as onset symptom in patient with COVID-19. Gut. 2020. DOI: 10.1136/gutjnl-2020-320891

405. Perlot T, Penninger JM. ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition. Microbes Infect. 2013;15(13):866-73. DOI: 10.1016/j.micinf.2013.08.003

406. Leung WK, To KF, Chan PK, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003;125(4):1011-7. DOI: 10.1016/j.gastro.2003.08.001

407. Klimpel KR, Molloy SS, Thomas G, et al. 1992. Anthrax toxin protective antigen is activated by a cell-surface protease with the sequence specificity and catalytic properties of furin. Proc Natl Acad Sci USA. 1992;89:10277- 81. DOI: 10.1073/pnas.89.21.10277

408. Yeoh YK, Zuo T, Lui GC, et al. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut. 2021 Apr;70(4):698-706. doi: 10.1136/gutjnl-2020-323020. Epub 2021 Jan 11. PMID: 33431578; PMCID: PMC7804842.

409. Liu F, Long X, Zhang B, Zhang W, Chen X, Zhang Z. ACE2 Expression in Pancreas May Cause Pancreatic Damage After SARS-CoV-2 Infection. Clin Gastroenterol Hepatol. 2020 Aug;18(9):2128-2130.e2. doi: 10.1016/j.cgh.2020.04.040. Epub 2020 Apr 22. PMID: 32334082; PMCID: PMC7194639

410. Kamal M, Abo Omirah M, Hussein A, Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2020: e13746.

411. Wade D. T. Rehabilitation after COVID-19: an evidence-based approach. Clin Med (Lond). 2020 Jul;20(4):359-365. doi: 10.7861/clinmed.2020-0353. Epub 2020 Jun 9. PMID: 32518105; PMCID: PMC7385804.

412. De Biase S, Cook L, Skelton DA, Witham M, Ten Hove R. The COVID-19 rehabilitation pandemic. Age Ageing. 2020 Aug 24;49(5):696-700. doi: 10.1093/ageing/afaa118. PMID: 32470131; PMCID: PMC7314277.

413. Lopez M., Bell K., Annaswamy T, Juengst S, Ifejika N. COVID-19 Guide for the Rehabilitation Clinician: A Review of Non-Pulmonary Manifestations and Complications [published online ahead of print, 2020 May 26]. Am J Phys Med Rehabil. 2020;10.1097/PHM.0000000000001479. doi:10.1097/ PHM.0000000000001479

414. Malyavin A.G., Adasheva T.V., Babak S.L., Governorova E.E., Uvarova O.V. Medical rehabilitation of patients who have undergone COVID-19 infection. Methodological recommendations (approved at the meeting of the Presidium of the RSMOT on June 15, 2020, minutes No. 2) Moscow 2020. 65 p. (In Russ.)@@ Малявин А.Г., Адашева Т.В., Бабак С.Л., Губернаторова Е.Е., Уварова О.В. Медицинская реабилитация больных, перенесших COVID-19 инфекцию. Методические рекомендации (утверждены на заседании Президиума РНМОТ 15 июня 2020 г., протокол №2) Москва 2020. - 65 с.

415. Wang F., Wang H., Fan J. et al. Pancreatic injury patterns in patients with COVID-19 pneumonia [published online ahead of print, 2020 Apr 1]. Gastroenterology. 2020;. doi:10.1053/j.gastro.2020.03.055

416. Han C., Duan C., Zhang S. et al. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. Am J Gastroenterol. 2020 Jun;115(6):916-923. doi: 10.14309/ajg.0000000000000664. PMID: 32301761; PMCID: PMC7172493.

417. Ling Y., Xu S. B., Lin Y. X. et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020 May 5;133(9):1039-1043. doi: 10.1097/CM9.0000000000000774. PMID: 32118639; PMCID: PMC7147278.

418. Tian Y, Rong L, Nian W, He Y. Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther. 2020;51(9):843- 851. doi:10.1111/apt.15731

419. Lee IC, Huo TI, Huang YH. Gastrointestinal and liver manifestations in patients with COVID-19. J ChinMedAssoc. 2020;83(6):521-523. doi:10.1097/ JCMA.0000000000000319

420. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M, Clark C, Iba T. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020 May;18(5):1023-1026. doi: 10.1111/jth.14810. Epub 2020 Apr 27. PMID: 32338827.

421. Hunt B et al. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. March 25, 2020 https://thrombosisuk. org/downloads/T&H%20and%20COVID.pdf

422. Gris J. C., Perez-Martin A., Quéré I., Sotto A. COVID-19 associated coagulopathy: The crowning glory of thrombo-inflammation concept. Anaesth Crit Care Pain Med. 2020 Jun;39(3):381-382. doi: 10.1016/j.accpm.2020.04.013. Epub 2020 May 4. PMID: 32418867; PMCID: PMC7196534.

423. Wade D. T. What is rehabilitation? An empirical investigation leading to an evidence-based description. Clin Rehabil. 2020;34(5):571-583. doi:10.1177/0269215520905112

424. Infusino F., Marazzato M., Mancone M. et al. Diet Supplementation, Probiotics, and Nutraceuticals in SARS-CoV-2 Infection: A Scoping Review. Nutrients.2020;12(6):E.1718. Published 2020 Jun 8. doi:10.3390/ nu12061718

425. Kryukov A. E. [Features of intestinal microbiocenosis in young people with community-acquired pneumonia]. Cand. Med. Sciences: 14.00.05. SPb., 2006. 27 p. (In Russ.)@@ Крюков, А. Е. Особенности кишечного микробиоценоза у лиц молодого возраста с внебольничной пневмонией: автореф. дис. … канд. мед. наук: 14.00.05 / Крюков Александр Евгеньевич. - СПб., 2006. - 27 с.